CA1071814A - Multilayer membrane useful as synthetic skin - Google Patents

Multilayer membrane useful as synthetic skin

Info

Publication number
CA1071814A
CA1071814A CA256,972A CA256972A CA1071814A CA 1071814 A CA1071814 A CA 1071814A CA 256972 A CA256972 A CA 256972A CA 1071814 A CA1071814 A CA 1071814A
Authority
CA
Canada
Prior art keywords
collagen
mucopolysaccharide
sulfate
moisture
multilayer membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA256,972A
Other languages
French (fr)
Inventor
Ioannis V. Yannas
John F. Burke
Philip L. Gordon
Chor Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of CA1071814A publication Critical patent/CA1071814A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/10Hair or skin implants
    • A61F2/105Skin implants, e.g. artificial skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60Materials for use in artificial skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00365Proteins; Polypeptides; Degradation products thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/08Collagen

Abstract

ABSTRACT OF THE DISCLOSURE
A multilayer membrane, which is useful as synthetic skin, is disclosed herein. A first layer is formed from a material which does not provoke an immune response and which is also insoluble and nondegradable in the presence of body fluids and/or body enzymes. Preferred materials for the first layer are crosslinked composites of collagen and a mucopolysaccharide.
A second layer is formed from a nontoxic material which controls the moisture flux of the overall membrane to about 0.1 to 1 mg./cm2/hr. Suitable materials for the second layer includes syn-thetic polymers such as silicone resins, polyacrylate or poly-methacrylate esters or their copolymers, and polyurethanes.

Description

!

` BACKGROUND OF THE INVENTION

1. Field of the Invention This invention is in the field of materials and more particularly in the field of materials suitable as synthetic skin.
2. Description of the Prior Art - References to attempts to cover open wounds and severe burns go back to 1500 B.C. Breasted, J. H., Edwin Smith, Surgical Papyrus, vol. l, Univ. of Chicago Press, Chicago, Illinois (1930), p. 83. Although a great déal of research effort has since been directed towards a functioning substitute for skin, no viable alternative for the autograft has yet been developed. However, the observations which have accumulated from the work atready done in this area of research have resulted in the evolution of a number of basic concepts which may be applied to the design of a system for treating open wounds and third degree burns with a more realistic expectation of success.
Prior approaches which have been used to develop a skin substitute can be divided into four broad catagories, namely: I
homografts; modified dermal xenografts; synthetic polymeric structures; and, reconstituted collagen films.
The use of homografts in the treatment of massive burns is an accepted procedure at the present time. The source of the skin transplant may be a live donor or skin obtained from cadavers and preserved in a skin bank. The justification for the use of homografts is the necessity for reducing fluid loss, preventing infections, and reducing the area of scarring.

~k 4~

`` 1071814 .
In the absènce of immunosuppressive agents, however, `~ homografts are almost invariably rejected. Rejection is apparently mediated primarily by the interception of graft vascularization which accompanies the onset of the immune reaction. Guthy, E. A., i Billotte, ~. B., Koumans, R. J. K., and Burke, J. F., in Research in Burns, Matter, P., Barclay, T. L. and Konickova, Z. (eds.), Hans Huber, Stuttgart, 1971. As is wèll known, the use of immuno-suppressive agents to avoid rejection of such grafts is al$o accompanied by a host of problems.
-`~? Efforts to modulate the immunogenicity of homografts by organ culture techniques have been attempted by several investi-gators. After a number of conflicting reports, the results of a ` definitive investigation of such prodedures was reported by Ninnemann and Good who concluded that modification of antigens in :
~`,3 the cultured tissue had not beèn demonstrated in such attempts.
Ninnemann, J. L. and Good, R. A., Transplantation, 18, 1 (1974).
` An alternative approach to the-use of homografts has been investigation of the possibility of modifying skin from animals. The basic goal of this approach is removal of those components in the dermis whi~h elicit the production of host antibodies.
Oliver et al. pursued this approach by treating porcine dermis with trypsin to remo~e cellular and non-collagenous material. Oliver, R~ F., Grant, R. A. and Kent, C. M., Brit. ~.
~5 ` Exp. Path,, 53, 540 (1972). this resulted in a graft material whichwas primarily insoluble collagen cast in the original morphology of the dermis, with a negligible level of antigenicity. The modified dermal collagen thus obtained was grafted on to full thickness excised skin wounds in the pig and its fate compared O to that of autografts and homografts of untreated dermis. The
- 3 -autografts behaved in the normal manner, described previously by Henshaw and Miller. Henshaw, J. R. and Miller, E. R., Arch.
Surq.~ 658 (1965). The untreated homografts were dead by Day 5 with mononuclear cells present~and had begun to degenerate at--the base by Day 10. By Day 20, the rejection of the homografts - was substantially complete. With treated dermal collagen grafts~
the lower part of the graft was repopulated with capillaries and fibroblasts by Day 5, while epidermal migration took place through the graft. Basophilic collagen lysis of the graft collagen started near Day 5 and was associated with infiltration of granulation tissue which progressively replaced collagen in the presence of multinuclear giant cells. By Day 20, the grafts were substantially replaced by granulation tissue and behaved like open wounds. This emphasizes the necessity for increasing the resistance of native collagen to lysis.
As a result of these experiments, Oliver et al. listed four requirements for a successful graft:
- 1. Dermal collagen fibers should persist unaltered for a long period, providing an essential structural framework for the reformation of the vascular and cellular elements of tissue;
2. The graft should not evoke foreign body reaction, which leads to eventual destruction of the newly cellularized graft;
3. The graft should provide a suitable dermal bed for the growth and development of normal epidermis; and,
4. The graft should suppress the formation of granula-tion tissue.
A third approach involves the use of synthetic polymeric structures. The literature is replete with references to the investigation of polymeric materials for a variety of biomedical ``` 1071814 , applications including skin substitutes or temporary wound dressings, This is not surprising in view of the polymer scien-tist's capability of incorporating almost any set of physical and chemical (but, as yet, few biological) requirements into a polymeric structure. The investigations into the utility of polymeric films as skin replacements have, thus far, eliminated - - -a considerable number of candidate materials but;have resulted in useful insights into the requirements for a satisfactory skin replacement. For example, the use of a-velours structure resulted O in improved adhesion to tissue, and the development of methods of preparation of so-called biocompatible polymers with controlled pore size improved the possibility of synthesizing materials capable of inducing cellular migration and proliferation into the graft. See Hall, C. W., Liotta, D., Chidoni, J. J.j Debakey, ~5 M. E., and Dressler, D. P., J. Biomed. Mat. Res., 1, 187 (1967);
and Wilkes, G. L. and Samuels, S. L., J. Biomed. Mat. Res., 7, 541 (1973), respectively. Another promising approach involved poly-merization of crosslinked polymers in the hydrogel form, thus providing added capability -for encouraging cellular ingrowth and 0 vascularization. Hubacek, J., K1iment, K., Dusek, J., and - Hubacek, J. Biomed. Mat. Res., 1, 387 (1967). The use of synthetic polymers in skin replacement has not so far led to solution of the problem, however, due mainly to the high incidence of infec-tion and the inability of the materials evaluated up to now to encourage vascularization and epithelization.
Since the major constituent of normal skin is collagen, a logical approach to the development of a skin substitute would involve study of the fate of reconstituted collagen structures when placed in contact with living tissue.

10718~4 This approach was used by a number of investigators using the general procedure of extracting the collagen from animals, purifying it to various degrees and converting it to' films or other structures that were used as wound dressi'ngs or implanted in living tissue to determine their in vivo fate.
Earlier work in this area demonstrated that collagen per se evokes a chronic inflammatory response with subsequent resorption of the implant. Pullinger, B. D. and Pirie, A., J. Path. Bact., 34,341 (1942). Grillo and Gross were able to show that the rate of resorption of collagen could be reduced by controlled cross-linking with formaldehyde. They`were also able to show that the immune response to reconstituted'collagen implants was minimal.
Grillo, H. C. and Gross, J., J. Surg. Res., 2, 69 (1962).
Enzymatically modified collagen has been prepared and evaluated by Rubin and Stenzel who showed that this treatment does not evoke as much cellular response as the untreated material.
The explanation for this variation in behavior is that the enzyme 'used (proctase)'effectively removes the te10peptides from the collagen molecule without destroying the native molecular struc-ture. Rubin, A. L. and Stenzel, K. H., in Biomaterials (Stark, L.
and Aggarwal, G., eds.)i Plenum Press, N. Y. (1969). The use of reconstituted collagen sheets has not eliminated the problems of lysis, tnfection and prevention of tissue ingrowth and vasculari-zation encountered by use of other approaches.

_ ~ _ `~

SUMMARY OF THE INVENTION
~ ~ .
This invention relates to a multilayer membrane which has properties necessary for artificial skin.
A first layer is nonimmunogenic, insoluble in the pres-ence of body fluids, and nondegradable in the presence of body enzymes. Preferred materials fo.r the first layer comprise cross-;

linked collagen-mucopolysaccharide composites, which are synthe-sized by intimately contacting collagen with a mucopolysaccharide and subsequently crosslinking the resultant product. Suitable .
collagens can be derived from a number of animal sources, and . .suitable mucopolysaccharides include, but are not limited to, chondroitin 4-sulfa-.te, chondroitin 6-sulfate, dermatan sulfate, keratan sulfate~ heparan sulfate, heParin. and hyaluronic acid.
Crosslinking can be achieved by chemical, radiation, dehydrothermal. or any other suitable technique. A suitable .-~ - chemical technique is aldehyde crosslinking, but other chemical crosslinking reactants are equally suitable. Dehydrothermal : crosslinking, which is pre~ferred, is achieved by reducing the ~
moisture level of the composites to a very low level, such as by subjecting- the composite material to elevated temperatures and high vacuum. Dehydrothermal cross.linking eliminates the necessity to add, and in the case of toxic materials such as aldehydes, to remove u.nreacted crosslinking agentsi dehydrothermal crosslinking also produces composite materials containing a wider range of mucopolysacc-haride.content.
The products.of such syntheses are believed to be comprised of collagen molecules or collagen fibrils with long mucopolysaccharide chains attached to them. Crosslinking appears .

.

`~' 107~81~
'i.......................................................... .
to anchor the mucopolysaccharide chains to the collagen so that they will not elute or otherwlse become disengaged. Mechanically, these materials can be thought of as analogous to fiber rein-., .
` forced composite materials wherein collagen is the fiber and ;~5 mucopolysaccharide is the matrix; therefore, these materials a-re . sometimes referred to herein as composite polymeric materials.
Crosslinked collagen-mucopolysaccharide co~posites have been found to retain the advantageous properties of native colla-;~` gen. Additionally, such materials can be synthesized to be non-0 antigenic, nondegradable by collagenase and other enzymes, and insoluble in the presence of body fluids. Additionally, such composites can be synthesized to have ultimate tensile strengths, elongations at break, and other mechanical properties particularly desired for artificial skin grafts and wound dressings.
~5 A moisture transmission control layer is adherently bonded to the first layer. This control layer is formed from a ~ nontoxic material which provides the overall membrane with a moisture flux of about 0.1 to about 1 mg/cm2/hr., which-is approxi-i mately the moisture flux of normal skin. Suitable materials for the moisture transmission control layer include synthetic polymers , such as silicone resins, polyacrylate or polymethacrylate esters or their copolymers, and polyurethanes.
Because of their unique combination of layers, the membranes described herein fulfill the functions required of i artificial skin or wound dressings. The rate of body moisture loss and heat loss from the damaged skin area is controlled to levels close to those with normal skin. Additionally, bacterial infection is prevented by these membranes and the wound area is protected from mechanical abrasion or other wear. Importantly, membranes formed from a first layer of a crosslinked collagen-mucopolysaccharide composites also provide a template for:

.
.~: ' ` " ' ,.

(1) the ~ngrowth and proliferation of cells from the subcutaneous tissue underlying damaged skin area or from epidermal tissue adjacent to the damaged skin area; the ingrowth and proliferation of capillaries and other blood vessels connected with the under-lying subcutaneous tissue or other tissue adjacent to the damaged area; and the development of new dermal tissue and epidermal tissue. These membranes also are capable of controlling the intensity, direction and rate of contractures as`sociated with the healing process.
.~ . .
..

BRIEF DESCRIPTION OF THE FIGURE

. The Figure -illustrates schematically a multilayer ~" membrane as described herein.
. .

; DESCRIPTION OF PREFERRED EMBODIMENTS-.:
The multilayer membranes described herein have at least two layers of different materials. As illustrated in the Figure, there is a first layer 10. Since layer 10 comes into direct con-tact with the subcutaneous tissue'or wound bed, there are three essential characteristics required of this layer. These are:
insolubility in body fluids; nondegradability upon contact with :; .
body enzymes; and nonimmunogenicity. These multilayer membranes also include at least one additional layer, which has the primary function of controlllng the moisture flux for the overall mem-brane. Thus, moisture transmission control layer 12 is illus-trated in the Figure as being directly bonded to the first layer.
It should be understood, however, that additional layers can be added on top of layer 12 or between first layer 10 and moisture control layer 12 as long as such additional layers do not inter-_ g _ ~` 1071814 fere with the essential functions of these lavers.
In addition to the aforementioned ,çssential proper-ties for the first layer, there are other properties which are ;~ highly desirable for this layer to possess.
` 5 One such desirable property relates to wetting and adhesion properties. It is desirable to form the first layer from a material which initially wets and adheres to a wound bed.
;~ These are prerequisites to the elimination of air pockets which may later become sites of bacterial proliferation. The immediate -~10 development of a moderately strong bond between a membrane graft and host tissue protects the graft from being displaced over the wound bed due to shear forces during bandaging or healing and thereby prevents air pockets from being formed. Therefore, it is preferred to use a material for the first layer which will quickly form a bond with host tissue having a shear strength of at least about 10 psi, and even more preferably of at least about 100 psi.
Further, it is desirable to use a material for the first layer which has mechanical properties which allow the membrane to "drape" over a wound bed and yet which resists tear during use. Thus, materials with a Young's modulus between about 100 and about 1000 psi, and an ult~mate tensile strength of at - least 100 psi,are preferred.
Epithelization of the membrane graft/epidermal tissue boundary provides a natural barrier to infection. Such a barrier can be formed by an epithelial sheet advancing over or through the graft, as illustrated in the Figure. Because of this, it is desirable to use a material for the first layer which allows epithelization velocities of at least about 0.1 mm/day.
-30 Infiltration of the multilayer graft with endothelial cells, fibroblasts and other cells, as illustrated in the Figure, 107181~
.
is a prerequisite for a graft that will serve as a template for neodermal tissue generation. Therefore, materials are preferred if they allow an infiltration rate of such cells of at least about 0.1 mm/day. This would allow cells to traverse about one-half of the thickness of a graft membrane having a typical thickness of 2 mm~in 10 days or less.
Preferred materials for the first l~ayer are crosslinked collagen-mucopolysaccharide materials. These are synthesized by contacting collagen with a mucopolysaccharide and subsequently crosslinking the resultant collagen-mucopolysaccharide product.
Collagen is a major protein constituent of connective tissue in vertebrate as well as invertebrate animals. It is , often present in the form of macroscopic fibers which can be . .
chemically and mechanically separated from non-collagenous tissue components. CoTlagen derived from any source is suitable, including collagen which is insoluble or is soluble in neutral, acidic and basic aqueous solutions, as well as those collagens which are commercially available. Typical animal sources include calfskin, bovine Achilles tendon and cattle bones.
~, .
The term mucopolysaccharide describes hexosamine-con-taining polysaccharides of animal origin. Another name often used for this class of compounds is glycosaminoglycans. Chemically, mucopolysaccharides are alternating copolymers made up of residues of hexosamine glycosidically bound and alternating in a more-or-less regular manner with either hexuronic acid or hexose moieties.
See Dodgson, K. S., and Lloyd, A. G., in Carbohydrate Metabolism and its Disorders, ed. by F. Dickens, et al., vol. 1, Academic Press (1968).
Some of the better known mucopolysaccharides derived from animals can be represented by the following structural formulas:

C~l OJI
H~ALUROI~IC ~o~

OB
CH,OH
COOII HO~
5CHONDROITIN ~' ~_I~ .
4-SULFATE ~OH )j----gH . NJlAo II.COS O~H
CHONDROITIN C~ . H~O~rO_ 6-SULFATE J¢OH .~r~,--Y
~_~ , , . NH~ o _011 CH.OH
HSSO ~0 1 0DERMAT~Y~

R.COSO-R

SULFATE lloF ~ ~--., ~1 ~;ll~o , .
H
pll ~OII Cll.oll COOH

15 =~ ~
MISO-R OH ~ NIISO-II OSO-B
HEPARî~ .

Ç~OOH H2COS03H
HEPARAN ~

OH NHSO3 It ~ 1071814 Other mucopolysaccharides are suitable for forming the composite materials described herein, and those skilled in the art will either know or be able to ascertain, using no more than routine experimentation, other suitable mucopolysaccharides. For a more detailed description of mucopolysaccharides, see the following reference, Aspinall, G.O., Polysaccharides, Pergamon Press, Oxford ~1970).

Typical sources of heparin include hog intestine, beef lung, bovine :liver capsule and mouse skin. Hyaluronic acid can be derived from rooster comb and human umbilical cords, whereas both of chondroitin 4-sulfate and chondroitin 6-sulfate can be derived from bovine cartilage and shark cartilage. Dermatan sulfate and heparan sulfate can be derived from hog mucosal tissues while keratan sulfate can be derived from the bovine cornea.
Collagen can be reacted with a mucopolysaccharide in aqueous solutions which can be either acidic, basic or neutral.
These reactions can be carried out at room temperature. Typically, small amounts of collagen, such as 0.3% by weight, are dispersed - in a dilute acetic acid solution and thoroughly agitated. The polysaccharide is then slowly added, for example dropwise, into the aqueous collagen dispersion, which causes the coprecipitation of collagen and mucopolysaccharide. The coprecipitate is a tangled mass of collagen fibrils coated with mucopolysa~charide which somewhat resembles a tangled ball of yarn. This tangled mass of fibers can be homogenized to form a homogeneous dispersion of fine fibers and then filtered and dried. Collagen-mucopolysaccharide coprecipitation products have been studied by Podrazky, V., - Steven, F. S., Jackson, D. S., Weiss, J. B. and Leibovich, S. J., Biochim. BiophYs. Acta., 229, 690 (1971).

.. ..

~071814 Although the collagen-mucopolysaccharide reaction.pro-duct coprecipitates from the aqueous medium from which it is formed, it has been found that the mucopolysaccharide component can dis-solve in other aqueous solutions. This is particularly true for more concentrated aqueous salt solutions, such as body fluids.
It is known, for example, that collagen-mucopolysaccharide copre-cipitates are insoluble in O.OlM NaCl, somewhat soluble in O.lM
NaCl, and quite soluble in 0.4M NaCl - the physiological level is about 0.14M NaCl. Thus, these reaction products have only limited insolubllity and are not suitable, per se, as candidate materials' for the first l'ayer.of multilayer membranes suitable for use as synthetic skin. - .
While the coprec'ipitation method described supra is preferred, collagen and mucopolysaccharides can be reacted in other ways. The essential requirement is that the two materials be intimately contacted under conditions which allow the muco-polysaccharides to attach to the collagen chains. Another suitable technique is to coat collagen with mucopolysaccharide, such as by dipping articles formed from collagen, including sheets, films, and tubes, into'a solution of mucopolysaccharide. A suitable variation of the latter technique involves prior coating with collagen of an article, sheet, film or tube fabricated from a non-collagenous material, such as a synthetic, natural or modified 'natural polymer, followed by dipping of the collagen-coated arti-cle, sheet, film or tube into the mucopolysaccharide solution.
Still another suitable method is to intimately mix colla~en with mucopolysaccharides, with each component in the form of a dry-powder.
To those skilled in.the art of forming sheets, films, tubes and other shapes or articles. by techniques that are known in the plastics, elastomerics and fiber-forming industries, it . .
would be obvious that the collagen-mucopolysaccharide product prepared as described above could also be formed into sheets, films, tubes and other shapes or articles by such techniques.
To gain any significant increase in resistance to collagen resorption, it is necessary to have at least about 0;5%
by weight of mucopolysaccharide bound to the collagen chains.
The upper limit may be set by the available sites on collagen for mucopolysaccharide to attach. For composites wherein the muco-polysaccharide is chondroitin 6-sulfate, levels of about 28% by weight have b-een achieved; with hyaluronic acid, on the other hand, the upper limit achieved is a~out 25%.
Reaction of collagen'with the mucopolysaccharides also provides collagen with another valuable property, i.e., inability to provoke an immune reaction (foreign body reaction) from an animal host. To convert collagen'into a màterial which, when ;mplanted, would not be recognized as a foreign body requires reacting it with it least about 1% by weight of mucopolysaccharide.
The degree of insolubility of the collagen-mucopoly-saccharide products can be raised to the desired degree by cross-linking these materials. In general, any crosslinking method suita-ble for crosslinking collagen is also suitable for cross-linking these composite materials. Such crosslinking serves to -- -prevent dissolution of mucopolysaccharide in aqueous solutions thereby making the materials useful for surgical prostheses, etc.
Crosslinking also serves another important function by contributing'to raising the resistance to resorption of these materials. The exact function of crosslinking is not understood in this regard, but it may be that crosslinking anchors the mucopolysaccharide units to sites on the collagen chain which would normally be attacked by collagenase.

~,` 1071814 .. ..
.
It has been found that the crossl~nked composites should have an Mc (number average molecular weight between crosslinks) of between about 800 and about 60000. Materials with Mc values below about 800 or above about 60000 suffer significant losses in their ; mechanical properties. Composites with an Mc of between about ` 5000 and about 10,000 appear to have the best balance of mechanical properties, and so are preferred materials.
Crosslinking can be achieved by many specific techniques with the general categories being chemical, radiation and dehydro-~) thermal methods. An advantage to most crosslinking techniques -` contemplated, including glutaraldehyde crosslinking and dehydro-thermal crosslinking, is that they also serve in removing bacterial .
growths from the materials. Thus, the composites are being steril-ized at the same time that they are crosslinked.
.
;j One suitable chemical method for crosslinking the coliagen-mucopolysaccharide composites is known as aldehyde cross-linking. In this process, the materials are contacted with aqueous - solutions of aldehydes, which serve to crosslink the mate-rials.
~ Suitable aldehydes include formaldehyde, glutaraldehyde and 3 glyoxal. The preferred aldehyde is glutaraldehyde because it yields the desired level `of-crosslink density more rapidly than other aldehydes and is also capable of increasing the crosslink , density to a relative!y high level.
Unreacted aldehydes should be removed from the collagen-; mucopolysaccharide materials since residual aldehydes are quite - toxic. It has been noted that immersing the composites in aldehyde solutions causes partial removal of the polysaccharide component by dissolution thereby lessening the amount of poly-saccharide in the final product.

Other chemical techniques which are suitable include ` carbodiimide coupling, a~ide coupling, and diisocyanate cross-;` linking.
A preferred crosslinking method is referred to herein as a dehydrothermal process. In dehydrothermal crosslink-ing, it is not necessary to add external crosslinking agents. The : `:
. key is to remove a large percentage of the water in the product to be crosslinked. The amount of water which must be removed will vary with many factors, but, in general, sufficient water to achieve the desired density of crosslinking must be removed.
- Thus, the collagen-mucopolysaccharide product can be subjected to elevated temperatures and/or vacuum conditions until the moisture content is reduced to extremely low levels. In the absence of vacuum, temperatures above about 80C, and preferably above 90C, can be used. At 23C, vacuum of at least about 10 5mm.
of mercury, and preferably below 10 6mm. of mercury, are suitable.
~ Elevated temperature and vacuum can be also used in combination;
t, this, in fact, is the most expeditious route and is therefore preferred. With a vacuum of at least about 10 5mm. of mercury, it is preferred to use a temperature of at least about 35C. In genera~! the materials are subjected to the elevated temperatures and vacuum conditions until the degree of insolubility desired -- is obtained. The higher the temperature, the lower is the vacuum required to arrive at a given crosslink density; and vice versa.
A typical crosslinking process to attain an Mc between about 5000 and 10000 would involve subjecting the collagen-mucopolysaccha-ride material to a temperature of 95C and a vacuum of 0.Olmm.
of mercury for 24 hours. Thfs dehydrothermal crosslinking pro-cess overcomes certain disadvantages of the aldehyde cross-linking method and produces composites having relatively large amounts of mucopolysaccharide strongly bound to the collagen chain.

; -17-Tlle exact mechanism operating in the dehydrothermal crosslinking process is not known. However, it may be either an amide condensation involving ~ -amino groups from collagen and carboxyl groups from the mucopolysaccharide component, or esterification involving carboxyl groups from collagen and hydroxyl groups from the mucopolysaccharide or esterification involving carboxyl groups from the mucopolysaccharide component and hydroxyl groups from collagen. Possibly all three mechanisms are involved to some extent. For a more detailed description of dehydrothermal crosslinking, see Yannas, I.V. and Tobolsky, A.V., "Crosslinking of Gelatin by Dehydration", Nature, vol. 215, #5100, pp. 509-510, July 29, 1967.

CrossLinked collagen-mucopolysaccharide composite materials are described in detail in the copending Canadian application entitled "Crosslinked Collagen-Mucopolysaccharide Composite Materials", by Huang and Silver, Serial No. 256,978 filed on July 14, 1976.

Crosslinked collagen-mucopolysaccharide composites can be synthesized which have all of the essential properties required for the first layer, and also possess many, if not all, of the desired properties thereof.
- The immunogenicity of collagen-mucoplysaccharide composite materials prepared as described supra is negligible as shown following implantation and grafting studies with guinea pigs. When implanted subcutaneously, or used as skin grafts, these materials elicit from the host tissue a mild inflammatory response represented by a few polymorphonuclear leukocytes and monocytes.
Lymphocytes are typically not observed either in the interior of these implanted or grafted materials or in the .

( 107181~

surrounding tissue. Collagen fiber synthesis has been frequently ;` observed to occur at the graft/host tissue interface, with forma-tion of fibrous bridges between the adjacent surfaces and a resulting mechanical anchoring of the implant on the host tissue.
The collagen-mucopolysaccharide composites, therefore, not only , possess very weak immunogenicity but, in addition, appear to be media which encourage fibroblast migr`ation and collagen synthesis.
A mechanochemical method was used to provide an in vitro measure of resistance to enzymatic degradation for the ) composites. This method involves stretching the composite ., , material to a fixed extension in the presence of a solution of collagenase and measuring the rate of relaxation of the force -induced on the material. Using bacterial collagenase, an expo-!;~ nential decrease in force with time was invariably observed. The ~ negative slope of the linear plot of logarithmic force versus '~7,' time (l/r) is taken as a measure of rate of enzymatic degradation.
The method produces data for collagen fibers consistent with - other known data obtained by subcutaneous implantation in guinea s.
pigs. Yannas, I. V., Burke, J. F., Huang, C. and Gordon, P. L., Correlation of In Vivo Collagen Degradatlon RatP With In Vivo : Measurements, J. Biomed. Materials Research, in press, 1975.
Using this method, it has been found that enzymatic degradation of collagen is strongly suppressed for crosslinked composites .j~, .
,~i wherein the mucopolysaccharide contains a sulfate group. These ; findings correlate very well with in vivo studies with guinea '. pigs.
Particularly preferred first layer materials are cross---- linked collagen-mucopolysaccharide composites containing between about 6% and about 15~ of a sulfate-containing mucopolysaccharide ~l and crosslinked to an Mc value of between about 5000 and about 10000. Chondroitin 6-sulfate forms especially outstanding com-posites.
.~ - 19 - .

:

- 1071819~

As described supra, the multilayer membranes also include a second layer which has the primary function of control-ling the moisture flux for the overall membrane, as illustrated in the Figure.
Moisture flows out of normal, undamaged human skin (forearm) at rates in the order of 0.5 mg/cm2/hr. ~pruit, D.
and Malten, K. E., Dermatoloqica, 132, 115 (1966). Following removal of the stratum corneum (and possibly of a part of the stratum granulosum) by "stripping" with adhesive tape, the mois-ture loss increases by 100-200 times to 60-100 mg/cm2/hr. This value is comparable to the evaporation rate at a free water surface, obtained under equivalent experimental conditions a-s above which is 85 mg/cm2/hr. Spruit-, D., Dermatoloqica, 141, 54 (1970).
Clearly, the stratum corneum is the major barrier of the skin against water loss since its removal leads to a rate of moisture loss which is almost identical to that occurring at the surface of free water. The efficiency of this moisture barrier is independent of the direction of water flow since it has been shown (by use of tritiated water) that the rate of permeation of liquid water through forearm skin is 0.6 mg/cm2/hr when the water is applied at the outside of the skin. Downes, A. M. Sweeney, T. M. and Matoltsy, A. 6., J. Invest. Derm., 49, 230 (1967).
In the design of a membrane useful as artificial skin, an effort has to be made to duplicate the value of moisture transmission rate for normal skin. Should the normal trans-mission rate values be exceeded, the host tissue in the neighbor-hood of the graft as well as the graft itself will become dehy-drated; tf, on the other hand, much lower transmission rates obtain, edema may result. These considerations apply, of course, only under conditions of intimate graft-host tissue contact;

- .

.

should substantial air pockets form at the interface, significant amounts of moisture from the host tissue may escape to the atmos-phere without passing through the graft.
Therefore, a moisture transmission control layer is formed from a material which provides a moisture flux per unit area for the overall membrane of at least about 0.1 to about 1 mg/cm2/hr. Preferably, the moisture flux per unit area is about 0.3 to about 0.5 mg/cm2/hr., which is approximately the range of human forearm skin. These values are obtained by an appropriate combination of thickness and water transmission properties.
The other essential property of this layer is that it be nontoxic. The material should contain no toxic substances capable of diffusing out into tissues contacting a multilayer membrane graft or capable of being extracted therefrom. Also, the material should be capable of resisting enzymatic degrada-tion or other degradation resulting from contact with other layers of the membrane or with tissue which degradation might lead to the production of substances that are toxlc to neighboring tissue.
As is the case with the first layer, there are several other desirable properties for the layer which primarily controls the moisture flux. Thus,`it is desirable that the moisture-control layer adhere to the wet surface of the first layer with a bond shear strength of at least about 10 psi, and preferably about 100 psi. It also is desirable that it have mechanical properties of: Young's modulus in the range of from about 100 to 1000 psij ultimate tensile strength of from about 100 to about 1000 psi; and elongation at break of from about 20 to about 100%.

., .
Additionally, it is advantageous if the moisture control layer is capable of being sterilized, i.e., of being subjected to physical or chemical treatment that kills bacteria and bacterlal spores on its sur~ace. Suitable sterilization techniques include dry heat, exposure to ethylene oxide, irradiation, immersion in glutaraldehyde solution, etc.
It is also desirable that the material constituting the moisture-control layer, when applied to the first layer in liquid or semiliquid form, not penetrate into the first layer more than about 20% by weight, of the final semisolid or solid-like, cured form of the first layer. Further penetration is deleterious because the porosity of the collagen-mucopolysaccha-ride layer would be seriously decreased and, consequently, mois-- ture transmission through and repair mechanisms occurring into the latter, such as tissue ingrowths, vascularization, etc., would be impaired.
Finally, it is also desirable that the moisture-control layer be capable of resisting-any degradation process, caused by its proximity or contact with adjacent layers or tissue, which would lead to significant impairment of the aforementioned bio-- logical~ mechanical and chemical properties.
Certain synthet-ic polymeric materials satisfy the essential, and many of the desirable, properties of the moisture control layer. Among these are: silicone polymers, such as Silastic*Medical Adhesive (Dow Corning), a mixture of an hydroxyl terminated silicone polymer and methyl triethoxy silane which moisture-cures into a flexible, tough layer that adheres very well to first layer materials such as crosslinked collagen-muco-polysacchari-de composites; polyacrylate or polymethacrylate esters or their copolymers such as an acrylic rubber latex formed from an ethyl acrylate-acrylic acid copolymer which forms a flexible * Trade Mark ~ - 2 2 ` film on top of first layer materials and which contains carboxy-lic acid groups capable of reacting with hydroxyl groups present : in crosslinked collagen-mucopolysaccharide materials to form` strong bonds; polyurethanes such as a reaction product of excess toluene diisocynate with a mixture of diols and triols to give a ` reactive, moisture-curing prepolymer capable of forming an elas-tomeric layer on crosslinked collagen-mucopolysaccharide compo-sites and having chemical groups which react with amino groups or ` hydroxyl groups in such composites. Those skilled in the art will ~10 recognize or be able to find, using no more than routine experi-,~ mentation, other materials which are suitable for the moisture control layer.
: Silicone.polymer is preferred as the moisture control ;~i layer. It is available as a non-toxic product in a carefully~15 controlled medical grade. Its flow properties are of thixotropic nature, permitting uniform application by knife blade onto the - surface of collagen-mucopolysaccharide composite layer with controlled penetration into the latter. Curing can be done at lOO~ relative humidity, thereby avoiding dehydratibn of the lower 570 layer, consisting of the collagen-mucopolysaccharide composite,;
and preventing deformation of the multilayered structure.
t, Silicone polymer cures by reaction with hydroxyl groups, and. since hydroxyl groups are present in the layer consisting of the ~ - collagen-mucopolysaccharide composite, sufficient covalent bonding ;'5 between layers is possible to form a satisfactory bond thereby obviating the need for an adhesive material to bond the silicone polymer layer to the layer consisting of the collagen-mucopoly-saccharide composite.
~; Multilayer systems can also be made by using a moisture-curing silicone elastomer as the agent bonding the collagen-muco-polysaccharide layer to another material. By applying a thin _ - 23 - -~ , .

film (1-2 thousandths of an inch) over a film prepared from synthetic polymers such as the segmented polyurethanes, hyd-roxy-..
:~` ethyl methacrylate and other "hydrogels", polyethylene terephtha-; late and polytetrafluoroethylene or from mo-dified natural polymers such as cellulose acetate or from natural polymers such as elastin (the fibrous, insoluble, noncollagenous protein found in connec-tive tissue such as the thoracic aorta and ligamentum muchae), a multicomponent composite can be obtained by curing at room tem-perature at 100% relative humidity for 16-24 hours.
~ 10 If mechanical reinforcement is desired, a layer of gauze -- or other fabric or mesh could be usefully employed. Cotton or other textile mesh can be incorporated as a reinforcing mechanism by placing the textile material over the collagen-mucopolysaccha-ride composite and applying the Silastic silicone over the mesh onto the collagen-mucopolysaccharide surface by knife coating.
Curing at room temperature and 100% relative humidity overnight (16-24 hours) can result in a reinforced composite which is some-what stiffer than one without the mesh but with substantially improved tensile strength.
The optimum thickness of a synthetic skin is related to the following parameters: (1) thickness of the skin to be replaced; (2) nature of wound and dimensions; (3) thickness of top layer required to control moisture flux; and, (4) relation ., of suturability to thickness.
~ 25 In the case of full thickness guinea pig skin, the average thickness of the excised skin is 25-30 mi-ls. Composites used to replace guinea pig skin comprise a layer of collagen-chondroitin 6-sulfate with a thickness of 15 mils and a layer of silicone polymer of 5 mils. Jhis combination provides moisture flux rates equal to that of the guinea pig skin and is easily sutured to the perimeter of the wound bed in grafting tests.
* Trade Mark ., .

`; ~ ` ( ~ `

The lowest attainable limit of thickness for the colla-gen-mucopolysaccharide layer is dependent upon the particle size of the collagen-mucopolysaccharide composites and is typical in the range of 1.5 - 2.0 mils. The upper limit of thickness depends only upon the application contemplated and in practice are available up to indefinitely high levels depending upon the quantity of dispersion filtered through a given area of ~, - filter. Thicknesses as high as 100-200 mils are readily pre-pared by the process herein described, although for application O as a skin substitute, the preferred range is 25-100 mils.
On the other hand, the thickness of the top layer would - be dictated by the desired moisture flux and the moisture vapor transmission properties of the polymer used to form the top ~ layer. In the case of Silastic Medical Grade silicone, a 5-mil ,.,~,?~ 5 thick silicone film layered onto a 15-mil thick layer of collagen-mucopolysaccharide composite is a typical multilayer artificial skin having the desired range of moisture flux. For polymers with lower rates of moisture vapor transmission rate, the mois-ture-control layer would have to be reduced in thickness propor- -o tionally.
- The multilayer membranes described herein are useful as dressings for the treatment of burns, cuts, lacerations, abrasions and other such conditions which involve injury or des-truction of skin by mechanical, thermal, chemical or other exter-nal insult by local or systemic disease. Also, the membranes themselves can be used as artificial grafts wherein they replace functions of normal skin and provide a template for cellular - regeneration.
The invention is further and more specifically illus-trated by the following examples.

*Trade Mark _ ~ .

`:

PREPARATION OF COLLAGEN DISPERSIONS
;
AND MUCOPOLYSACCHARIDE SOLUTIONS
: !
.` .
The collagen used was prepared by precutting limed calf hides into strips 3/8" wide and then into thin pieces.
;~ These thin pieces of hide were contacted with three parts of water containing 0.3% propionic acid and 0.1% benzoic acid.
- Equilibrium was established after four hours at which time the ,...................................................................... I
'~~ 10 solution had a p~l approaching 5.3. The collagen slurry was - ~ separated from the water and ground to products of different ~- particle sizes and structures with a centrifugally acting cutter- --- grinder. The calf hide collagen slurry (1:1 water-to-hide weight ~' ratio) had a gelatin content of about 2~. Additionally, it contained about 0.41% calcium and about 0.041% magnesium. Phy-,~ - sically, the slurry was composed of highly entangled fibrillar aggregates.
The calf hide collagen slurry was purified by a repeated precipitation from a turbid dispersion in 0.05 M acetic acid with 0.2 M sodium dihydrogen diphosphate, NaH2PO4. After purification, collagen was dispersed in 0.05 M aceticacid or in a citric acid-buffer solution at pH 3.2 (0.1 M citric acid, 0.2 M
sodium dihydrogen diphosphate). The dispersion was thoroughly ~` homogenized in a Waring Blender until the absorbance at 440 millimicrons of a 0.3% (W/V) collagen dispersion was about 0.5 as !`
measured on a spectrophotometer (Coleman Junion II A, Maywood, ; Illinois). The resulting collagen dispersions were stored at 4C until further processing was required.
; 30 - !

~` -26-" j ` 107~814 Mucopolysaccharide solutions were prepared from ~ sodium heparin, hyaluronic acid and chondroitin 6-sulfate. So-``` diùm heparin, from hog intestinal mucosa, 143 U.S.P. units of ~` activity per milligram, was purchased from Abbott Laboratories, :~ North Chicago, ILlinois. Hyàluronic acid, from rooster comb `~ was prepared by the method of Swann, D.A., Biochim, Biophys.
Acta, 156, 17 (1968). The resulting hyaluronic acid contained ~i ~47.1% hexuronic acid and 42.6% hexosamine.
Chondroitin 4-sulfate from bovine nasal cartilage was prepared by the method described by Roden, L., Baker, J.R., Cifonelli, J.A. and Mathews, M.B., in Methods of Enzymology!
~ , V. Ginsburg, ed., vol. 28B, Academic Press, New York, p. 73.
~ - Heparan sulfate and dermatan sulfate were both extracted from - hog mucosal tissues and purified by the methods described by Cifonelli, J.A and Roden, L., Biochemical Preparations,12, 12 (1968). - -Chondroitin 6-sulfate, from shark cartilage -- Grade B, was purchased from Calbiochem, San Diego, California.
It contained 2.66% nitrogen, 37.2% glucuronic acid and 5.61% mois-ture. -`
IIeparin, hyaluronic acid, chondroitin 4-sulfate, heparin sulfate, dermatan sulfate and chondroitin 6-sulfate were dissolved (1% W/V) in a citric acid-phosphate buffer pH 3.2.
The mucopolysaccharide solutions were stored at 4C.

.--.
;. .
. . .

; 30 .

` 1071814 PREPARATION OF COLLAGEN-HEPARIN AND
COLLAGEN-HYALURONIC ACID COPRECIPITATES

Collagen 0.3g (W/V) dispersed in 0.05 M acetic acid was thoroughly agitated with a Teflon stirrer at 23C. While the dis-persion was mixing, heparin or hyaluronic acid 1~ (W/V) in 0.05 M
acetic acid was added drop wise from a buret at the rate of about ; 0.1 ml. per second. The addit~ion of mucopolysaccharide caused collagen to coprecipitate forming a tangled mass of collagen fibrils coated with mucopolysaccharide which somewhat resembled a tangled ball of yarn. When 90X by weight of collagen was co-.
precipitated in this manner with lOX by weight mucopolysaccharide, a systematic mass balance showed th-at about 95% of the original mucopolysaccharide was coprecipitated.
After coprecipitation, the tangled mass of fibrils was homogenized in a Waring Blender until the fibrils were about 1 mm.
in length. The mixture of fibriis in 0.05 M acetic acid sepa-- rated into two phases when left unagitated for more than five minutes, so that mixing was required before filtration. Filtra-tion was performed by filtering the collagen-mucopolysaccharide dispersion under vacuum through a Buchner funnel containing Schleicher and Schuell (Keene, New Hampshire) filter paper No-. 576.
The coprecipitate was allowed to dehydrate under atmospheric con-ditions until the moisture content was about 20% by weight.
: *Trade Mark _ 28 --.
_ . --. .

Collagen 0.3% ~W/V) dispersed in a citric acid-phosphate buffer solution pH 3.2 at 23C was coprecipitated with a 1% (WtV) chondroitin 6-sulfate buffer solution pH 3.2 at 23C. The coprecipitate was homo-genized, filtered and allowed to dry in the atmosphere as described in Esample 2.

ALDEHYDE CROSSLINKING OF A COLLAGEN-Coprecipitated collagen-chondroitin 6-sulfate as prepared in - Example 3 was crosslinked by immersing it in a 0.02 M solution of glutar-aldehyde. This treatment effectively immobilized a fraction of the poly-~ saccharide component on the collagen fibrils or molecules. Crosslinking was evidenced by the inability to remove the polysaccharide from the aldehyde-treated film by prolonged washing with a phosphate buffer solution containing 0.4 M sodium chloride, pH 7.4, which is a well known solvent of chondroitin 6-sulfate. Unreacted aldehydes were removed by treatment with a solution of 5,5-dimethyl-1,3-cyclohexane dione (dimedone). Evaporation of the water left behind a film containing up to about 10% by weight poly-saccharide.

, .

.

: ~ 1071814 .

The product of Example 3 was placed in a vacuum oven and exposed to a temperature of 115C and a vacuum of at least 0.3mm. Hg. for 48 hours. At the end of this treatment, less than 10 weight percent of the polysaccharide originally incorporated-into the film could be removed by 48-hour immersion in distilled water, a solvent for chondroitin 6-sulfate.

.

HEXOSAMINE ANALYSIS AND MOLECULAR WEIGHT BETW~EEN CROSSLINKS
.'~ . - .
Since mucopolysaccharides are hexosamine-containing polymers, th~e level of hexosamine is directly related to the amount of a specific mucopolysaccharide in a composite material.
Once a relationship is established between the hexosamine content S ~ and weight for each individual mucopolysaccharide, the determina-tion is straightforward. This analysis is described in detail by Huang, C., Sc. D. Thesis, Mech. Eng. Dept., M.I.T., Cambridge, Mass., Chaps. 3, 4 (1974). The method is summarized as follows.
A known weight of a vacuum dried (48 hours at 105C) composite is placed in a 5 ml. ampule-and 1 ml. of 8 M HCl is added. The ampule is evacuated and flushed with nitrogen gas followed by sealing under vacuum. Hydrolysis is initiated when the ampule is placed in a circulating air oven at 95C. After 4 hours at 95C, the ampule is cooled with tap water to 10C. The contents of the tube are then evaporated to dryness at 40C until only the dry hydrolyzate remains.- The hydrolyzate is dissolved in distilled ' ' .

~ 1071814 i~
water to give a concentration of about 50-150 mg. of mucopolysaccharide per ml. of water. One ml. of the hydrolyzate solution is added to 1 ml.
of an 8% (V/V) solution of acetylacetone in 1 M Na2C03. After heating at 95C for 1 hour, hexosamine contained in the hydrolyzate reacts with acetylacetone in alkaline solution to form derivatives of pyrrole. Upon cooling the solution to 10C, 5 ml. of 95% ethanol and 1 ml. of Ehrlich reagent (prepared by dissolving 1.33g. of p-dimethylamino-benzaldehyde, DAB, in 50 ml. of 6 M HCl to which 50 ml. of 95% ethanol is added) are added followed by thorough mixing. The reaction between DAB and derivatives of pyrrole results in the formation of a chromophore which colors the product an intense red. After the mixture is allowed to stand for 2 hours, the absorbance is measured at 527 millimicrons against a reagent blank using a Coleman Junior II A spectrophotometer. The results of the analysis are compared to standard calibration curves for each mucopolysaccharide.
The results of hexosamine analysis on several crosslinked collagen-- mucopolysaccharide materials prepared by the methods of previous Examples are presented in Table I. The mucopolysaccharide content before crosslink-ing was determined to be about 10% for each composite listed in Table 1.
It appears that during glutaraldehyde crosslinking and subsequent washing steps, large quantities of mucopolysaccharide were lost. This implies that the solubility of uncrosslinked mucopolysaccharides is high in the aqueous glutaraldehyde solution in which the former are immersed for the purpose of crosslinking them. For the dehydrothermally crosslinked composites, only 10%, at most, of a mucopolysaccharide was eluted, versus up to 61% for the glutaraldehyde process.
The mechanical properties of the composite materials is strongly influenced by the number of crosslinks per polymer .: , .

.

. , .
chain. The molecular weight between crossl~nks (Mc) ~s inversely proportional to the number of crosslinks per unit volume. By measuring the stress-strain behav~or of thermally denatured colla-` gen-mucopolysaccharide composites, values of Mc can be determined.
The technique is described by Treloar, L.R.G., The Physics of Rubber Elasticity, Second Edition, Clarendon Press (1958). A
summary of experimental results for several collagen-mucopoly-saccharide composites is also presented in Table I.

TABLE I

Material -Crosslinking X MPS Mc (+ 10~) .. .
Collagen G (24, 7.4) 0.0 1,500 Collagen-H G (24, 3.2) 5.7+1.29,400 Collagen-H G (48, 7.4) 5.5+1.31,200 Collagen-H G ~24, 3.2 4.0+1.01,800 24, 7.4) Collagen-H D (48, 90C) 9.7+1.02,800 Collagen-CS-6 G (?4- 3.2) 3 9+ 3 6,800 Collagen-CS-6 D (48, 90C) -9.6+1.1 1,200 Collagen-HA G (24, 7.4) 2.3+.4 2,200 Collagen-HA D (48, 9-0C) 9.0+.5 2,500 G Glutaraldehyde at 23C (hours, pH) D = Dehydrothermal thours, temp.) H = Hepar~n CS-6 = Chondroitin 6-sulfate HA = Hyaluronic Acid ' 10~71814 COMPOSITES FORMED BY COATING COLLAGEN WITH MUCOPOLYSACCHARIDES
,. ..
Mucopolysaccharide solutions were prepared by dissolving 40 mg. of the mucopolysaccharide in 20 ml. citric acid-phosphate buffer (pH 3.2), A length of an insoluble collagen film was then added to the mucopolysaccharide solution and maintained at a constant temperature of 37C and allowed to incubate for about 24 hours. Glutaraldehyde was then added to the solution to give a resultant concentration of 0.025 M-of aldehyde. The collagen was kept in this solution for another 24 hours and was-subse-quently transferred to a 0.025 M solution of glutaraldehyde maintained at a pH of 7.4. The latter step was done in order to insure efficient crosslinking of collagen. After 24 hours in the glutaral'dehyde solution, the collagen'fibers were rinsed three times with distilled water and transferred to a 0.2 weight percent solution of dimedone in order to remove excess, unreacted aldehydes. After another 24 hours in the dimedone solution, the fibers were rinsed five times with distilled water and kept in a citric acid-phosphate buffer solution at pH 7.4 at 4C. The weight percent of mucopolysaccharide attached to the collagen was determined by hexosamine analysis. The molecular weight between crosslinks, Mc, was determined using the procedure des-cribed in Treloar, L.R.G., The Physics of Rubber Elasticity, 2nd ed.', Clarendon Press (1958). The results are presented in Table Il.
-~

.

` TABLE II
.'~ - ..
Material X MPS (+0.5) Mc (+500) .
Collagen 0 3800 Collagen-CS-6 11.3 4100 Collagen-CS-4 8.7 4000 Collagen-HA 8.2 4200 Collagen-DS 8.2 3900 Collagen-H 8.7 3800 Collagen-KS 10.5 3800 .
CS-6 = Chondroitin 6-sulfate DS = Dermatan Sulfate CS-4 = Chondroitin 4-sulfate H = Heparin HA ~ Hyaluronic Acid KS ~ Kera~an Sulfate , .

. - 34 -10718~4 ENZYMATIC DEGRADATION OF COMPOSITES FORMED
FROM COLLAGEN COATED WITH MUCOPOLYSACCHARIDE

A study of the enzymatic degradation of composites formed by coating a mucopolysaccharide onto collagen fibers as described in Example 7 was made. The mucopolysaccharide-coated collagen films, in the form of tape, were extended to a strain of 4.0+0.5% in the presence of a solution of collagenase (40-units/ml.') and the force induced on the tape was recorded as a function of time. The force was found to be representa-ble by a single negative exponential of the time and hence a plot of the logarithmic force versus,time yields a straight line. The slope of the straight line yields ljr'- a value which is taken as a measure of the rate of enzymatic degradation of the collagen by the collagenase. The results are presented in Table III.

- TABLE III
,:
- - 1/T X 104 (+0.07) Material X'MPS (+0.5) (min-l) - , Collagen - O ~ 8.48 Collagen-CS-6 11.3 1.46 Collagen-CS-4 8.7 0.88 Collagen-HA 8.2 5.38 Collagen-DS ' 8.2 0.90 Collagen-H 8.7 0.98 Collagen-KS ' 10.5 1.10 .

ENZYMATIC DEGRADATION OF COMPOSITES FORMED
., Crosslinked composites of collagen and chondroitin 6-sulfate prepared according to the method of Example 4 were tested for their susceptibility to collagenase degradation.
The technique used is described in the previous Example except that the strain imposed was 20+2~. The results are presented in Table IV.

TABLE IV

l/r X 102 (+o.oog) % CS-6 (+0.2) Mc (~1000) (min-l) O 15000 0.255 1.8 14000 0.149 3.0 12000 0.153 4.8 . 13000 0.093 6.5 11000 0.084 8.6 90Q0 0.049 11.2 1000~ - 0.052 . 13.3 12000 0.047 - . 14.9 11000 . 0.064 16.0 14000 0.067 ~ 1071814 MECHANICAL PROPERTIES OF CROSSLINKED COLLAGEN-MUCOPOLYSACCHARIDE COMPOSITE MATERIALS

` Mechanical testing was done on an Instron tester using a B-type load cell. Dumbell shaped specimens 0.25 in. wide and about 0.01 in. thick were prepared for each candidate material.
The top end of the specimen was attached to the load cell of the Instron while the lower end was attached to the crosshead through a clamping device. The strain on the specimen was calculated based on the crosshead movement. All measurements were conducted at a constant elongation rate of 50%/minute in tension at 37~C
in a citric acid-phosphate buffer solution at pH 7.4.
Values of the force per unit area at rupture or ultimate tensile stress (U.T.S.), tangent to the stress-strain curve at 1%
elongation (lX tangent modulus), elongation at break (E.B.), and work required to fracture (fracture work) were calculated for each material from the experimental stress-strain curve.
Ihe results are presented in Table V below.

.

' *Trade Mark ~ - .

107181~
,~
~ o o_ 3 O O O O O O o O o O O O O O
+I OO O OOO o o o o C~ OO
0~ 0 W O 0~ N _ ~ cy _CO ~D 0 N 0 ~ -- -- _ U~

.~_. . ...

m In . ~ c~l _ c~J N . t~) NC~
.~ oo +l +i +~ +l +l +l +l +i +l +l +l +l +l -U~ U~ O ~ ~ O ~
_ _ ~ J O
. '~a . T
ll ~) ~ O U~ ~ . O O O O O O 0 00 0 . ~ ~ O u~ O O O O O N ~ _ o I ~
-- Cl~ N ~ ~ ~ ~ ~ c~ ~ o~ ~ ~ ~ 4_ . V~
~D
~-._ a~ v) O 1-) 0 0 0 o o o N O t~JIf ) O --c _ ._ Ln ~+ ~ + ~ + ~ + ~ + ~~+ ~ + ~ + I + I $ 1 + I + I
a ~ ~ u~u~ o o o ~ u~ o o ~ ~ ~ o o ~
1--~ ~ ~ O It~ O O 1~ 0 0 ~ N11~ 0 ~ C C
~ L~ w C~let ~ cn ~ ~ ~ I~ ~ ~ s . . . al 11 ~ . D ' J o o o o o o o o o o o o o I_ ~) O O ~D CO - U~ C~
al ~ ~ . o~ ~ N ~ ) N _ N
.' N C~l O N ~ ~ ~ _ U~
O O O O _ _ _ _ O O
O O O + I + l ' + I + I + I +l +l n u~ ~ ~ ~ ~ ~ ~ o~
U~
: - S
_ ~ ~ ~ . ~ ~ _ ~ ~ ~ ~ ~ ~ ~ O
_ O O 1~ ~ C~JC~l o ~t N N~ - O O ~) ~ O O ' O ' O O C~J ~
._ o~ ~ s v~ ~ w ~ ~ ~ a~ ~ d w ~ w00 In ~ ~ O ~J ~ ~ ~ ~ N d- C~l d d' ~ --O _ _ _ _ _ _ _ ~_ _ _ _ _ _ ~ ~
O O ~ ~ ~ ~ C~ ~ ~ C ~ ~ -. _ ~>
- a o _ O - V~ S ~ O
L O C C C C C C C C C C C C C

s o o o o o o o o o o o o o n - O u~

.

. 1071814 .

INCREASED TOUG~NESS DUE TO
.. I
INCORPORATION OF MUCOPOLYSACCHARIDES

Comparison of specimens of collagen and crosslinked collagen-mucopolysaccharide composites at similar crosslinking levels suggests that the presence of the mucopolysaccharide significantly increases toughness of collagen. For example, the fracture work at similar levels of crosslinking from materials taken from the preceeding Table are presented in Table VI below.

TABLE VI

.
- Fracture Work Material % MPS Mc (psi-%) +10%

Collagen 0.0 1200 1900 Collagen-CS-6 9.6+1.1 1200 7100 As can be seen, the incorporation of about 10 weight percent chondroitin 6-sulfate in collagen increases the fracture work from about l90b to about 7100 psi-%. Since the fracture -work is maximal at an Mc levei of about 6500,-it appears likely that a collagen-chondroitin 6-sulfate composite with about 10 weight percent of the mucopolysaccharide and an Mc equal to about 6500 might possess a fracture energy greater than about 11,000 psi-%, the maximum fracture energy recorded for pure collagen under the conditions of these tests;

EXA_PLE 12 IN VIVO TESTING OF RESORPTION RESISTANCE OF AND
ABSENCE OF FOREIGN BODY REACTION TOWARDS COMP SITES
: .
In this Example, crosslinked collagen-mucopoly-saccharide membranes, prepared both by coating collagen with each ~` of the mucopolysaccharides as described in Example 7 as well as .~ .
, by coprecipitating collagen with each of the mucopolysaccharides as described in Examples 2 and 3 were implanted subcutaneously i in guinea pigs as described below.
The collagen-mucopolysaccharide membranes had been sterilized by the process used to crosslink them. Immersion in -~ an aldehyde bath (and, in particular, in a glutaraldehyd~ bath) over several hours as described in Example 4, is well-known as an effective means of chemical steriiization of a variety of materials prior to implantation or other surgical procedures.
It is also known that exposure to temperatures in exc~ss of 100C
. over several hours is an aLternative method of sterilization of ~, materials that will be implanted or otherwise used in surgery.
In addition, however, if the materia-ls have been prepared consi-derably prior to grafting it is preferable to disinfect them just before grafting by immersion in 70/30 isopropanol~water for 24 hours at 23C. Immersion in the latter-medium does not alter either the crosslink density or other important structural features of collagen-mucopolysaccharlde composites.

.

.

( ~0~1814 .
, Subcutaneous implantation was carried out under aseptic conditions. White, Hartl-ey, female-guinea pigs, weighing approxi-mately 400 grams were used as subjects. For 7 days prior to implanta-tion, a weight-change history was recorded for each animal.
Shortly before im-plantation, the back of each animal was sheared with electric clippers over an area of ca. 6 cm X 5 cm and loose hair clippings were carefully removed with vacuum suction. The animal was then anesthesized by exposure to a mixture of oxygen and halothane, and its back was washed with 70/30 isopropanol/
water.
A one-inch incision was made on one side of the back of the animal.~ The incision was made such that a pocket between the dermis and the panniculus carnosus was created. The specimen was inserted into this pocket such that the whole specimen lay flat within the pocket. The incisi-on was then sutured with nylon sutures. A total of about 5 to 6 stitches were made to close the ~ncision. The procedure was repeated with the other side of the guinea pig back, using an identical specimen. The right side was subsequently used for histological studies while specimens from the left side were, after explantation, used for physico-chemical characterization.
On the 4th, 10th, anq 20th postimplantation days, the animals were sacrificed by placing them in a desiccator containing ether. From both the left and right implantation sites, 1-112" X 1-1/2" squares of the tissues were cut below the subcuta-neous layer such that the implanted specimens remained in the tissue. The tissue from the right side was placed in a 10% for-malin solution and was subsequently used for histological studies as described below. The tissue from the left side was immersed in sterile Dulbecco's solution (50 ml) containing a few drops of --.

chloroform (which acts as a bactericide) and stored under refrig-eration for not more than 24 hours before the sample within it was removed.
Removal of the sample within the tissue was done by placing the tissue on the stage of a low powered microscope (e~uipped with' a camera) and stripping the subcutaneous tissue from the dermis in such a way that the state of the sample within the tissue-could be examined clearly with the microscope. This could be achieved by first cutting between the dermis and the subcutaneous tissue and gently separating the two part's by means of forceps. When viewed on the microscope, the state-of the tissue and the sample embedded within it could be examined to reveal such features as the attachment of tissues to the implanted material. Removal of the sample from the tissue was done on the microscope stage by means of a forceps. After the materials had been removed from the tissue they were stored in Dulbecco's solution at 4C until 'required to determine the following physico- -chemical properties: -1. The fractional weight change of the sample AW/W;.
This was obtained by determinlng the dry weight of'the samples (after dehydration at 105C at a pressure of 10-3 mm. Hg. for 48 hours). The fractional weight change was then calculated as - . . .
We - Wj A W / W j whePe We = dry weight of the explanted samp-le, and Wj = dry weight of the sample prior to implantation (the latter was determined by use of a control).
~ 2. Tensile modulus, E, (in dynesjcm2). This was ; obtained by the method described in Example 10 except that the `

.
modulus was determ~ned as the slope of the stra~ght portion of the stress-strain curve. '' 3. Molecular weight between crosslinks, Mc.' This was measured as descr~bed in Example 4.
- The characteristics of collagen-mucopolysa'ccharide speci-mens just before implantat-ion as well as on the 4th, 10th and 20th days following implantation are presented in Table VII for materials -- th-at were prepared by coating collagen,with various mucopolysac-charides prior to crosslinking and in Table VIII for materils pre-pared by coprecipitating collagen with mucopolysaccharides prior to crossllnking.

.

U

o ~ o U~ o ( po~ ~ ~ o ~0r' ~a I O O +l o o +l o o O ~ ~ ~ ~D ~
~ ~ .+o ~ ~r $ ~r ~ +o~ u~
J~ . .
~ . . .
!a o . o ~r -'~q ~ O ~ o ~ ~ . o ~ ~ . +, o o . +, o o . U~ +
O o o co r~ -o ~ o o r~
.P ~1 0+ ~ ~r $.~ ~ ~
.
. ~ ' . ~ o ~ o ~. ", o 0 +, o o +, o o +o, o o . ~ ~D +l +l ~ +l +~ . ~ +l +~
O - u~ ~D . O a~ ~ o o o~
.' . . :~
O ~ . J~' ' .~ ~ ~r ~ ~ ~ .:
0 _1 0. ~ In O ~ .n ~ O ~ u~
~ cn +l o o +l o o ' +l o o ~ ~ o o CO .~ . o ~ CO' ~ o o~ o '~ ~ o ~ ~ ~ o ~ ~ ~ o ~ ~ - . -.

P~ :~ . :~ a ~ . .' l oq Ql ~ ~ ~ ~î ~ ~

G o So E ,~ o 3.1 lo E o 3 , ~o X
O _ E3 ~ S:O _ ~ U _ , ~

U~ o U~

107181~
. ..
., a~ . o .~ ~ o o ~a O +, +, o ~

C~ ~ U~
~ to ~ U~
tq ~ o ~ ~ +l o o ~ ~ ~o`
`-? ~1 T~
.~
. . o 0 . ~, ... .
~ o - ,~1 +, o . o +, . +, ~r o , : o .
a~
C ~
O ~1 ~~r . . , - .
o ~ ~o . ~ U~
~ o ", ~+, o o ~. ,~ o +~ +, P. ~ o o ,, ~, .
.~ O o ~r ~ -a~ ~
P~ g C _' - ' ' .
I
a~
. lo 3~ lo ~
_~ ~ _~
O ~ Ul X
C~ <3 X
o ~ ~ - æ
ro ~D
_ U~

u ~ ~ o ~ ~ o ~ 3 o l~u ~ ~ ~u ~ X ~ ~I~x ~., o U~

~1' .

(~ ( 107~814 ' . ` , O
+, o o U~
~D 1` ~D
o +
. '~ .
:
: ,~ ~ .
~ ~ +, o o ~ ~ ~+, +, o o ~
': ' ,, + -' '' .
H .
1' O `
~'~ O
.'~` . ~ +l O O
;' OU~ ~
. o ,,0 ~ l ~
10 ~ O
. ~ _I .
~ ~ O . . ..
~1 ~ +10 '. O - ' _~ ~ O +l +l E~ O o a) o ~ ~ O
P' S
C~ .
. OP
l _' .
U~ ~ t`.l Q~ 3 .,1 00~ O
J~ N ~rl I U --I
~1 _i 3 l U~ X
~ _~ 3 a) O <IX ~ C) . _ _ :

S~

( .
It is clear from Table VII and VIII that in almost all cases where collagen was crosslinked wlth a mucopolysaccha.ride, either after being coated or coprecipitated with a mucopoly-saccharide, the fractional weight loss was arrested indicating that the degradatlon of collagen had been effectively abolished by reaction with the mucopolysaccharide. The only exceptions were collagen coated with hyaluronic acid (a nonsulfated muco-polysaccharide) and collagen coprecipitated with only 1.8 weight percent chondroitin 6-sulfate; in the latter case, the-fractional weight loss of collagen was delayed rather than arrested completely.
In all other cases, an occasional very small initial weight loss, - possibly due-to deswel-ling of-the implanted.specimen, was reversed usually by the 10th day until, by the 20th day, the implant was . --heavier than when implanted. The increase in weight of the im-plant-was found to be due to adherence of some of the surrounding tissue onto the implant as the.latter was removed from the animal.
. The tissue adhering on the implant was analyzed and found to be - ..-.constituted almost entirely of-col-lagen, an observation showing that new collagen had been synthesized on the lmplant by cells in the surroundi-ng tissues. Thus, not only did reaction with the sulfated mucopolysaccharides-prevent degradation of collagen but also yleld-ed a composite material capable of eliciting synthesis of new connective tissue on its surface by cells in the surround-ing tissue.
The protection from resorption afforded to collagen by reaction with sulfated mucopolysaccharides is also evident in the prevention of the substantial decrease in modulus E a-nd decrease in crosslink density (increase in Mc) which is observed with collagen itself or with a collagen-hyaluronic acid composite.
The maintenanc.e of E and Mc to relatively steady levels (within ~07181~

the experimental uncertainty) up to 20 days of implantation for composites of collagen and one each of the sulfated mucopoly-saccharides is indicative of a crosslinked macromolecular network which remains intact for at least 20 days in the tissue of the `~` 5 living animal.
Histological studies were performed on the tissue/implant block removed from the right side of the animal on the 4th, 10th ~` and 20th days. The standardized procedure used in preparing the~- =specimens for histological examination was the following: -1. - The tissue was fixed in 10% forma-lin (Fischer Scientific Co., NJ) for at least 24 hours at room temperature.
~ , - - 2. It was then dehydrated by sequen~ial immersion in ~- water-ethyl alcohol mixtures containing 50~j 70~, 85~, ~5% and~ lOOg alcohol, the time of immersion being 1 hour per mixture.
'-15 - 3. The tissue was then immersed in dioxane for 2 hours before it was embedded in a tissue-embedding medium (Paraplast, ,` Mpt. 56-57C; Curtin Scientific Co., Houston, Texas). Embeddingwas-achie-ved by first placing the tissue in the molten paraffin kept at 58C for 4 hours, with hourly exchanges for the paraffin.
Finally, the tissue was placed in a mould and embedded with a -- fresh supply of paraffin.
4. The paraffin block containing the tissue was then - coo1ed to 0C in a bath containing chipped ice for 20 minutes and ;` ` was then mounted on a microtome (Minot Custom Microtome; Interna-tional Equipment Co., Needham Heights, MA). Slices of the paraf-fin containing the tissue were microtomed to thicknesses of about .~ 6~.
- 5. The microtomed specimen w-as then mounted on a clear microscope slide- and deparaffinization was achieved by immersing o th~ mounted specimen in two exchanges of xylene for 3 minutes each.
` ' , - ~0 -( ` 10718~4 ." . ...
6. The spec~men was then rehydrated by sequential immersion in water-ethyl alcohol mixtures containing 100~, 95%, 85%, 70%, 50% and 0% alcohol, the t~me of immersion being 1 hou'r per mixture. The specimen was finally rinsed thoroughly with '~' ' distilled water.
7. The specimen was then st-ained with hematoxylin for ~ 5 minutes and rinsed briefly with distilled water. Excess stain '~ was removed by rinsing the specimen with 0.5X acid alcohol ~70X
~' ethyl alcohol in concentrated hydrochloric acid). The acid alcohol '` was finally removed by rinsing the specimen and immersing it in ', water for 1/2 hour.
. . .
8. The specimen was then stained with 0.5% aqueous ' eosin for 3 minutes and then rinsed with 5 exchanges of water.
9. The speci'men was dehydrated as in (2) above and ~" then rinsed a few times with xylene. -
10. It was then mounted on a clean cover slip with a permanent mounting medium (Harleco Synthetic Resin; Hartman-, Leddon Co., Philadelphia, PA).
11. The cover slip containing the stained specimen wasexamined with a microscope.
'' - The histological studies revealed that the extent and ~' severity of chronic inflammation in the tissue surrounding the ''' collagen'implant decreased steadily as the content of chondroitin '. 6-sulfate in a series of implants based on coprecipitated collagen-chondroitin 6-sulfate comFosites increased in the range 1.8 to 11.2 weight percent. These results showed that while the ~. .
collagen used in th'e composite materials provoked, when used by itself, a moderate immune response, reaction of the collagen with chondroitin 6-sulfate led to practically complete suppression of ' this immune response. These findings were also made when the " - 51 -.

;

`` 10718~4 .. . .
implant was based on compos1te materials prepared by coating collagen with one of the sulfated mucopolysaccharldes. In summary, the histological observations showed that the ability of implanted collagen to provoke a foreign body reaction from the animal host could be controlled and suppressed by react;on with one each of the sulfated mucopolysaccharides.

.. .
.

~'- ` ' ' ' .

.

, . .

, . . ' .

~,~ 1071814 PREPARATION OF BILAYER COMPOSITE_EIAVING A FIRST LAYER
OF COLLAGEN-C~IOND~OITIN~ 6-SULFATE ANV A SECOND LAYER
FO ~

One hundred and fifty ml. of a 0.67% by weight collagen dispersion, prepared as in Example 1, was mixed with I
50 ml. of citric acid-phosphate buffer, pH 3,2, containing 0.2 grams chondroitin 6-sulfate under high-speed stirring. The resultant precipitate was filtered onto a Schleicher and Schuell filter paper, #589, 11 cm in diameter through a Buchner funnel.
The resultant composite film of collagen-mucopolysaccharide was removed from the filter paper and immersed in 0.02~ solution of glutaraldehyde and processed as in Example 4. The thickness of the resultant film was 15-17 mils.
The composite film was then blotte~ dry and a 5-mil coat of medical Grade Silastic silicone adhesive type A (Dow Corning Co.) was applied to the surface by knifing with a spatula.
The coated composite was placed in a dessicator at 100% RH and 73C for 16 hours. The resultant coated film was evaluated as a synthetic skin after sterilization in isopropyl alcohol and washing in sterile distilled water and sterile Dulbecco's solution.

*Trade Mark ~.

IN VIVO GRAFTING OF MULTILAYER SYNTHETIC SKIN

Collagen-chondroitin 6-sulfate composites coated with silicone resin, prepared as in Example 13, were cut to the desired dimensions (4 cm X 6 cm) and immersed in 70/30 isopropanol/
water for 24 hours at 23C for disinfection. Handling of speci-mens was done in a sterile atmosphere supplied by a Tenney Relia-lab Laminar flow hood. Surgeon's gloves and masks were used during specimen handling. Following removal from the alcohol~
solution, the specimens were washed twice with sterile distilled water and then stored in Dulbecco's solution at 4C until needed.
At the end of this procedure, bacteriological testing of colla-gen-chondroitin 6-sulfate specimens for gram positive and gram negative bacteria and for anaerobics routinely gave negative re-sults.
Grafting was carried out under aseptic-conditions.
White, Hartley, female guinea pigs, weighing approximately 400 grams were used as subjects. For 7 days prior to grafting, a weight change history was recorded for each animal. Shortly before grafting the back of each animal was shearéd with electric .
- clippers over an area of 6 cm X 5 cm and loose hair clippings carefully removed with vacuum suction. The animal was then anesthesized by exposure to a mixture of oxygen and halothane and its back washed with 70/30 isopropanol/water.
Incisions covering an area of 4 cm X 6 cm were made according to an outline, made with iodine solution, which con-formed to the size of the graft. The skin was excised over the panniculus carnosus, taking care to induce only minimal bleeding.

Any blood in the wound was removed by patting with sterile gauze pads wet with sterile saline. The graft was placed over the wound bed in close juxtaposition to the skin at the perimeter of the wound. The graft was affixed by suturing with nylon suture, using approximately 16 sutures to close the wound. The animal was covered with a bandage encircling its body and secured around the neck to prevent slippage. Each animal under test was housed in a separate cage for the duration of the experiment.
The animals under test were weighed each day and the weight recorded. After 5 days the bandage was opened and the graft site examined. Animals were sacrificed at varying intervals and the graft and wound bed excised, and divided into two equal sections. One section was submitted for histological examination and the other examined without further treatment under a low-powered microscope. By lifting the graft material from the tissue with suitable tweezers, an examination of the condition of the wound site and the graft could be made. For periods up to at least 10 days, there was evidence of tissue undergrowth into the graft and no indication of wound contraction or acute inflammation.
- Epitheliazati~n was minimal at the perimete~ of the wound bed.

A collagen-chondroitin 6-sulfate composite prepared in accordance with Example 5 was grafted on a guinea pig in accor~nce with procedure in Example 14. After suturing, the entire graft and about 1/8" of neighboring skin was coated with a collodion solution (cellulose ester in suitable organic solvent) and allowed to dry thoroughly before application of bandage. The behavior of graft and tissue was similar to that of Example 14 except that by the 10th day the coating cracked due to embrittlement and dehydra- -tion of the collagen-chondroitin 6-sulfate layer occurred,, with consequent contraction of the wound and epitheliazation along the edges of the wound site.
Those skilled in the art will know, or be able to ascer-tain by no more than routine experimentation, many equivalents to the specific embodiments expressly described herein. These are within the scope of this invention and are intended to be covered by the appended`claims.
,

Claims (24)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A multilayer membrane, comprising:
a. a first layer formed from a crosslinked collagen-mucopolysacchar-ide composite containing at least about 0.5% by weight mucopolysaccharide; and, b. a moisture transmission control layer formed from a nontoxic material, said moisture transmission control layer providing said multilayer membrane with a moisture flux of from about 0.1 to about 1 mg/cm2/hr.
2. A multilayer membrane of claim 1 wherein said moisture trans-mission control layer is formed from a natural polymer.
3. A multilayer membrane of claim 1 wherein said moisture trans-mission control layer is formed from a synthetic polymer.
4. A multilayer membrane of claim 3 wherein said collagen-mucopolysaccharide composite contains a sulfate-containing mucopolysaccharide.
5. A multilayer membrane of claim 4 wherein said collagen-mucopolysaccharide composite contains from about 6% to about 12% by weight of said sulfate-containing mucopolysaccharide.
6. A multilayer membrane of claim 5 wherein said sulfate-containing mucopolysaccharide is selected from chondroitin 6-sulfate, chondroitin 4-sulfate, heparin, heparan sulfate, keratan sulfate or dermatan sulfate.
7. A multilayer membrane of claim 6 wherein said collagen-mucopolysaccharide composite is crosslinked to an Mc value of between about 800 and about 60,000.
8. A multilayer membrane of claim 7 wherein said sulfate-containing mucopolysaccharide is chondroitin 6-sulfate.
9. A multilayer membrane of claim 8 wherein said moisture trans-mission control layer is formed from a synthetic polymer selected from silicone resins, polyacrylate esters, polymethacrylate esters and polyurethanes.
10. A multilayer membrane of claim 4 wherein said moisture trans-mission control layer is formed from a synthetic polymer selected from silicone resins, polyacrylate esters, polymethacrylate esters and polyurethanes.
11. A multilayer membrane of claim 8 wherein said moisture trans-mission control layer is formed from a silicone resin.
12. A multilayer membrane of claim 11 wherein said moisture trans-mission control layer provides said multilayer membrane with a moisture flux of from about 0.3 to about 0.5 mg/cm2/hr.
13. A multilayer membrane of claim 12 having an overall thickness of from about 25 to about 100 mils.
14. A multilayer membrane of claim 1 having an overall thickness of from about 25 to about 100 mils.
15. Synthetic skin comprising a first layer formed from a cross-linked collagen-mucopolysaccharide composite bonded to a nontoxic moisture transmission control layer which provides said synthetic skin with a moisture flux of from about 0.1 to about 1 mg/cm2/hr.
16. Synthetic skin of claim 15 wherein said moisture transmission control layer is a synthetic polymer.
17. Synthetic skin of claim 16 wherein said synthetic polymer is selected from silicone resins, polyacrylate esters, polymethacrylate esters and polyurethanes.
18. Synthetic skin of claim 16 wherein said synthetic polymer is a silicone resin.
19. Synthetic skin of claim 18 wherein said collagen-mucopoly-saccharide composite material contains from about 6% to about 12% of a sulfate-containing mucopolysaccharide and wherein said composite is crosslinked to an Mc value of from about 5000 to about 10,000.
20. Synthetic skin of claim 19 wherein said sulfate-containing mucopolysaccharide is chondroitin 6-sulfate.
21. Synthetic skin of claim 20 having an overall thickness of from about 25 to about 100 mils.
22. Synthetic skin of claim 15 having an overall thickness of from about 25 to about 100 mils.
23. Synthetic skin comprising a multilayer membrane having a first layer formed from a crosslinked collagen-mucopolysaccharide composite and a moisture control layer which provides the multilayer membrane with a moisture flux substantially equal to normal skin.
24. A multilayer membrane, useful as synthetic skin, comprising:
a. a first layer formed from a crosslinked collagen-mucopoly-saccharide composite material which: (1) has controllable degradability in the presence of body enzymes; (2) has controllable solubility in the presence of body fluids; (3) is substantially nonimmunogenic upon grafting or implanta-tion; and, (4) provokes no substantial foreign body response upon grafting or implantation; and, b. a moisture transmission control layer which provides the multi-layer membrane with a moisture flux substantially equal to normal skin.
CA256,972A 1975-07-15 1976-07-14 Multilayer membrane useful as synthetic skin Expired CA1071814A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/596,112 US4060081A (en) 1975-07-15 1975-07-15 Multilayer membrane useful as synthetic skin

Publications (1)

Publication Number Publication Date
CA1071814A true CA1071814A (en) 1980-02-19

Family

ID=24386029

Family Applications (1)

Application Number Title Priority Date Filing Date
CA256,972A Expired CA1071814A (en) 1975-07-15 1976-07-14 Multilayer membrane useful as synthetic skin

Country Status (6)

Country Link
US (1) US4060081A (en)
JP (1) JPS5238796A (en)
CA (1) CA1071814A (en)
DE (1) DE2631909C2 (en)
FR (1) FR2332863A1 (en)
GB (1) GB1518748A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282300A1 (en) * 2003-08-26 2012-11-08 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289125A (en) * 1976-11-01 1981-09-15 International Paper Company Polymeric sheets
CH625702A5 (en) * 1977-01-18 1981-10-15 Delalande Sa
US4154857A (en) * 1977-03-22 1979-05-15 Union Carbide Corporation Collagen dewatering with polysaccharides
JPS6019725B2 (en) * 1977-10-04 1985-05-17 ポ−ラ化成工業株式会社 skin cosmetics
US4725279A (en) * 1979-01-22 1988-02-16 Sterling Drug Inc. Bio compatible and blood compatible materials and methods
US4439391A (en) * 1979-06-26 1984-03-27 International Paper Company Polymeric sheets
US4306563A (en) * 1979-11-28 1981-12-22 Firma Pfrimmer & Co. Pharmazeutische Werke Erlangen Gmbh Catheter for introduction into body cavities
US5120813A (en) * 1980-02-29 1992-06-09 Th. Goldschmidt Ag Moisture vapor permeable materials
US4522753A (en) * 1980-07-17 1985-06-11 Massachusetts Institute Of Technology Method for preserving porosity in porous materials
NZ197782A (en) * 1980-07-30 1985-07-31 Smith & Nephew Ass A moisture vapour transmitting elastic bandage
US4306552A (en) * 1980-08-12 1981-12-22 The United States Of America As Represented By The Secretary Of The Navy Plasticized poly-ε-caprolactone film
US4361552A (en) * 1980-09-26 1982-11-30 Board Of Regents, The University Of Texas System Wound dressing
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4539716A (en) * 1981-03-19 1985-09-10 Massachusetts Institute Of Technology Fabrication of living blood vessels and glandular tissues
US4546500A (en) * 1981-05-08 1985-10-15 Massachusetts Institute Of Technology Fabrication of living blood vessels and glandular tissues
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
US4350629A (en) * 1981-07-29 1982-09-21 Massachusetts Institute Of Technology Procedures for preparing composite materials from collagen and glycosaminoglycan
JPS5846961A (en) * 1981-09-16 1983-03-18 株式会社バイオ・エンジニアリング・ラボラトリ−ズ Blood compatible polyvinyl chloride and production thereof
FR2517315B1 (en) * 1981-11-30 1985-12-20 Tech Cuir Centre PROCESS FOR THE PREPARATION OF NEW FORMS OF COLLAGEN, NATIVE OR DERETICULATED, WITH PRESERVED HELICOIDAL STRUCTURE, ASSOCIATED WITH MUCOPOLYSACCHARIDES AND THEIR APPLICATIONS IN PARTICULAR IN THE COSMETOLOGICAL, PHARMACEUTICAL, ANALYTICAL AND OTHER FIELDS
US4424208A (en) 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
CA1213520A (en) * 1982-03-17 1986-11-04 Abe Widra Hydrophilic biopolymeric copolyelectrolytes, and biodegradable dressings comprising same
US4570629A (en) * 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
US4787900A (en) * 1982-04-19 1988-11-29 Massachusetts Institute Of Technology Process for forming multilayer bioreplaceable blood vessel prosthesis
EP0107711A4 (en) * 1982-04-19 1985-10-24 Massachusetts Inst Technology A multilayer bioreplaceable blood vessel prosthesis.
US4820302A (en) * 1982-04-22 1989-04-11 Sterling Drug Inc. Bio compatible and blood compatible materials and methods
IL65855A (en) * 1982-05-24 1986-09-30 Yeda Res & Dev Prosthetic tendon
JPS58222739A (en) * 1982-06-19 1983-12-24 三菱電機株式会社 Charging system controller
CA1212879A (en) * 1982-07-21 1986-10-21 Laszlo Juhasz Composite wound dressing
JPS59181158A (en) * 1983-03-30 1984-10-15 日東電工株式会社 Wound cover agent
US4448718A (en) * 1983-09-13 1984-05-15 Massachusetts Institute Of Technology Method for the preparation of collagen-glycosaminoglycan composite materials
GB2148901A (en) * 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4808570A (en) * 1984-02-24 1989-02-28 University Of California Compositions and method for improving wound healing
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
US4837285A (en) * 1984-03-27 1989-06-06 Medimatrix Collagen matrix beads for soft tissue repair
CA1295796C (en) * 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
GB8413319D0 (en) * 1984-05-24 1984-06-27 Oliver Roy Frederick Biological material
JPS60261460A (en) * 1984-06-11 1985-12-24 株式会社 高研 Artifical skin comprising collagen and poly-alpha-amino acidmembrane
JPS6141452A (en) * 1984-08-02 1986-02-27 株式会社 高研 Artificial skin
US4801475A (en) * 1984-08-23 1989-01-31 Gregory Halpern Method of hydrophilic coating of plastics
US4664658A (en) * 1984-11-08 1987-05-12 Mitsubishi Monsanto Chemical Company Medical material and process for its production
GB2170713B (en) * 1985-02-13 1988-10-05 Tpo Pharmachim Human skin substitute for temporary use
US4861714A (en) * 1985-04-04 1989-08-29 Verax Corporation Weighted collagen microsponge for immobilizing bioactive material
US5100783A (en) * 1985-05-10 1992-03-31 Verax Corporation Weighted microsponge for immobilizing bioactive material
FR2585576B1 (en) * 1985-07-30 1992-01-03 Bioetica Sa BONE MATRIX REPLACEMENT PROMOTING OSTEOGENESIS
US4663233A (en) * 1985-10-24 1987-05-05 Universal High Technologies Lens with hydrophilic coating
DE3608158A1 (en) * 1986-03-12 1987-09-17 Braun Melsungen Ag VESSELED PROSTHESIS IMPREGNATED WITH CROSSLINED GELATINE AND METHOD FOR THE PRODUCTION THEREOF
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
IT1198449B (en) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
US4798611A (en) * 1986-10-14 1989-01-17 Hancock Jaffe Laboratories Enhancement of xenogeneic tissue
DE3751254D1 (en) * 1986-10-31 1995-05-24 Nippon Zeon Co Wound dressing.
US6309635B1 (en) 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
CA1340581C (en) * 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US4813942A (en) * 1987-03-17 1989-03-21 Bioderm, Inc. Three step wound treatment method and dressing therefor
US4751935A (en) * 1987-04-09 1988-06-21 Lee Pharmaceuticals Artificial fingernail
US5273900A (en) * 1987-04-28 1993-12-28 The Regents Of The University Of California Method and apparatus for preparing composite skin replacement
FR2616318A1 (en) * 1987-06-15 1988-12-16 Centre Nat Rech Scient ARTIFICIAL SKIN AND PROCESS FOR PREPARING THE SAME
US5108438A (en) * 1989-03-02 1992-04-28 Regen Corporation Prosthetic intervertebral disc
US5258043A (en) * 1987-07-20 1993-11-02 Regen Corporation Method for making a prosthetic intervertebral disc
US5681353A (en) * 1987-07-20 1997-10-28 Regen Biologics, Inc. Meniscal augmentation device
US5735902A (en) * 1987-07-20 1998-04-07 Regen Biologics, Inc. Hand implant device
US5263984A (en) * 1987-07-20 1993-11-23 Regen Biologics, Inc. Prosthetic ligaments
US5158574A (en) * 1987-07-20 1992-10-27 Regen Corporation Prosthetic meniscus
US5116374A (en) * 1989-03-02 1992-05-26 Regen Corporation Prosthetic meniscus
US4880429A (en) * 1987-07-20 1989-11-14 Stone Kevin R Prosthetic meniscus
US5007934A (en) * 1987-07-20 1991-04-16 Regen Corporation Prosthetic meniscus
US5306311A (en) * 1987-07-20 1994-04-26 Regen Corporation Prosthetic articular cartilage
US4947840A (en) * 1987-08-21 1990-08-14 Massachusetts Institute Of Technology Biodegradable templates for the regeneration of tissues
US5015584A (en) * 1987-10-14 1991-05-14 Board Of Regents, The University Of Texas System Epidermal graft system
US5350583A (en) * 1988-03-09 1994-09-27 Terumo Kabushiki Kaisha Cell-penetrable medical material and artificial skin
DE68909933T2 (en) * 1988-03-09 1994-03-03 Terumo Corp FOR CELL-PULLABLE MEDICAL MATERIAL AND ARTIFICIAL SKIN.
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
JPH06104116B2 (en) * 1988-11-29 1994-12-21 三菱化成株式会社 Wound dressing
US5726009A (en) * 1989-03-20 1998-03-10 Anticancer, Inc. Native-state method and system for determining viability and proliferative capacity of tissues in vitro
US6004261A (en) * 1989-04-28 1999-12-21 C. R. Bard, Inc. Formed-in-place endovascular stent and delivery system
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US20030077825A1 (en) * 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5635482A (en) * 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5354736A (en) * 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5674848A (en) * 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
HUT63319A (en) * 1990-04-24 1993-08-30 Mark Eisenberg Method for producing composition equivalent with living skin
US5645591A (en) * 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US8067149B2 (en) * 1990-09-12 2011-11-29 Lifecell Corporation Acellular dermal matrix and method of use thereof for grafting
AU654574B2 (en) * 1991-06-14 1994-11-10 Amgen, Inc. Collagen film drug delivery for proteins
US5610753A (en) * 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
DE9203684U1 (en) * 1992-03-19 1992-07-02 Pohl, Yango, 6350 Bad Nauheim, De
WO1994012510A1 (en) * 1992-11-30 1994-06-09 Lane I William Processing shark cartilage
US5725577A (en) * 1993-01-13 1998-03-10 Saxon; Allen Prosthesis for the repair of soft tissue defects
US5514378A (en) * 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US6689608B1 (en) 1993-02-01 2004-02-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation
US6017359A (en) * 1993-05-25 2000-01-25 Vascular Solutions, Inc. Vascular sealing apparatus
US5383896A (en) * 1993-05-25 1995-01-24 Gershony; Gary Vascular sealing device
US5868778A (en) * 1995-10-27 1999-02-09 Vascular Solutions, Inc. Vascular sealing apparatus and method
US5518680A (en) * 1993-10-18 1996-05-21 Massachusetts Institute Of Technology Tissue regeneration matrices by solid free form fabrication techniques
US6280771B1 (en) 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US6176874B1 (en) 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
GB9400163D0 (en) 1994-01-06 1994-03-02 Geistlich Soehne Ag Membrane
US5489304A (en) * 1994-04-19 1996-02-06 Brigham & Women's Hospital Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft
US5695777A (en) * 1994-05-10 1997-12-09 Medtronic, Inc. Absorptive wound dressing for wound healing promotion
US5704907A (en) * 1994-07-22 1998-01-06 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US6102045A (en) * 1994-07-22 2000-08-15 Premier Laser Systems, Inc. Method and apparatus for lowering the intraocular pressure of an eye
US5520631A (en) * 1994-07-22 1996-05-28 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5554106A (en) * 1994-10-13 1996-09-10 Quinton Instrument Company Hydrocolloid exit site dressing
US5569207A (en) * 1994-10-13 1996-10-29 Quinton Instrument Company Hydrocolloid dressing
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US7008634B2 (en) * 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
US6262255B1 (en) 1995-04-05 2001-07-17 Biomm, Inc. Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them
US6123727A (en) * 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
WO1997006837A1 (en) * 1995-08-16 1997-02-27 Integra Lifesciences Corporation Perforated artificial skin grafts
JP2000504333A (en) 1996-01-29 2000-04-11 ドワロン,シャルル Prion-free collagen and collagen-derived products and implants for a number of biomedical applications;
ES2208974T3 (en) * 1996-08-23 2004-06-16 Cook Biotech, Inc. PROTESIS OF GRAFT, MATERIALS AND METHODS.
EP0842670A1 (en) * 1996-11-13 1998-05-20 Katsunari Nishihara Biomedical materials
CA2295163A1 (en) * 1997-06-26 1999-01-07 Smith & Nephew Plc Cell culture products
FR2766717B1 (en) * 1997-08-01 2000-06-09 Cogent Sarl COMPOSITE PROSTHESIS FOR PREVENTION OF POST-SURGICAL ADHESIONS AND PROCESS FOR OBTAINING SAME
US5925053A (en) 1997-09-02 1999-07-20 Children's Medical Center Corporation Multi-lumen polymeric guidance channel, method for promoting nerve regeneration, and method of manufacturing a multi-lumen nerve guidance channel
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production
DE69903800T2 (en) 1998-03-18 2003-10-02 Massachusetts Inst Technology VASCULARIZED PERFUNDED ARRANGEMENTS FOR MICRO TISSUE AND MICROORGANES
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
US6013122A (en) 1998-08-18 2000-01-11 Option Technologies, Inc. Tattoo inks
US6214054B1 (en) * 1998-09-21 2001-04-10 Edwards Lifesciences Corporation Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
WO2000016822A1 (en) * 1998-09-21 2000-03-30 The Brigham And Women's Hospital, Inc. Compositions and methods for tissue repair
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US20030225355A1 (en) * 1998-10-01 2003-12-04 Butler Charles E. Composite material for wound repair
US6454811B1 (en) 1998-10-12 2002-09-24 Massachusetts Institute Of Technology Composites for tissue regeneration and methods of manufacture thereof
US6479072B1 (en) * 1999-02-11 2002-11-12 The General Hospital Corporation Microfabricated membranes and matrices
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6371984B1 (en) 1999-09-13 2002-04-16 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
ES2491866T3 (en) 1999-11-15 2014-09-08 Piramal Healthcare (Canada) Limited Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution
US7560275B2 (en) * 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
ATE398468T1 (en) * 2000-03-03 2008-07-15 Syntacoll Ag AGENTS FOR WOUND TREATMENT
US6974679B2 (en) * 2000-05-26 2005-12-13 Coletica Support with collagen base for tissue engineering and manufacture of biomaterials
BR0112109A (en) 2000-06-29 2007-05-29 Biosyntech Canada Inc composition and method for the correction and regeneration of cartilage and other tissues
US20020151050A1 (en) * 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
US7041868B2 (en) 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Bioabsorbable wound dressing
KR101012952B1 (en) 2001-02-14 2011-02-08 안트로제네시스 코포레이션 Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2002067908A1 (en) * 2001-02-26 2002-09-06 Duke University Novel dendritic polymers and their biomedical uses
US6833488B2 (en) 2001-03-30 2004-12-21 Exotech Bio Solution Ltd. Biocompatible, biodegradable, water-absorbent material and methods for its preparation
US7226611B2 (en) * 2001-04-02 2007-06-05 Yaizu Suisankagaku Industry Co., Ltd. Glycosaminoglycan/collagen complexes and use thereof
US6913762B2 (en) * 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US7494482B2 (en) 2001-05-15 2009-02-24 The Brigham And Women's Hospital, Inc. Methods and apparatus for application of micro-mechanical forces to tissues
CN1226974C (en) * 2001-05-16 2005-11-16 苏珊娜·伊丽莎白·查默斯 Wound dressings and wound treatment compositions
AU2002345691C1 (en) * 2001-06-13 2008-07-24 Massachusetts Institute Of Technology In vivo bioreactors
RU2264294C2 (en) * 2001-08-24 2005-11-20 Мэттью Р. КУУК Method of making cup handle
US20050260179A1 (en) * 2001-11-06 2005-11-24 The General Hospital Corporation D/B/A Massachusetts General Hospital Stem and progenitor cell capture for tissue regeneration
GB2382775B (en) * 2001-12-06 2005-05-25 Johnson & Johnson Medical Ltd Controlled release therapeutic wound dressings
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US20040131582A1 (en) * 2002-02-26 2004-07-08 Grinstaff Mark W. Novel dendritic polymers and their biomedical uses
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
CA2480875A1 (en) * 2002-04-01 2003-10-16 Board Of Regents, The University Of Texas System Composite material for wound repair
WO2003092468A2 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
US8187326B2 (en) * 2002-05-22 2012-05-29 Advanced Technologies And Regenerative Medicine, Llc. Attachment of absorbable tissue scaffolds to fixation devices
US6989034B2 (en) 2002-05-31 2006-01-24 Ethicon, Inc. Attachment of absorbable tissue scaffolds to fixation devices
AU2003249310A1 (en) * 2002-07-17 2004-02-02 Proxy Biomedical Limited Soft tissue implants and methods for making same
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
KR101095771B1 (en) * 2002-09-18 2011-12-21 워쏘우 오르쏘페딕 인코포레이티드 Natural tissue devices and methods of implantation
US7309359B2 (en) * 2003-08-21 2007-12-18 Warsaw Orthopedic, Inc. Allogenic/xenogenic implants and methods for augmenting or repairing intervertebral discs
US20040054414A1 (en) * 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
JP2006515765A (en) 2002-11-15 2006-06-08 エスディージーアイ・ホールディングス・インコーポレーテッド Collagen-based materials and methods for treating synovial joints
US20040121943A1 (en) * 2002-12-20 2004-06-24 Wei-Cherng Hsu Drug-free biodegradable 3D porous collagen-glycosaminoglycan scaffold
US7544368B2 (en) 2002-12-20 2009-06-09 Life Spring Biotech Co., Ltd. Structure for modulating intraocular pressure
FR2861734B1 (en) * 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
WO2005003300A2 (en) 2003-06-04 2005-01-13 University Of South Carolina Tissue scaffold having aligned fibrils, apparatus and method for producing same, and methods of using same
US8465537B2 (en) 2003-06-17 2013-06-18 Gel-Del Technologies, Inc. Encapsulated or coated stent systems
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
US20050220907A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Implanted medical devices with anti-inflammatory coatings
EP1773978B1 (en) * 2004-05-19 2014-04-02 Massachusetts Institute Of Technology Perfused three-dimensional cell/tissue disease models
WO2005115259A2 (en) * 2004-05-24 2005-12-08 Biomedical Strategies Wound closure system and methods
US20050271712A1 (en) * 2004-06-04 2005-12-08 Shannon Donald T Multilayer wound covering and therapeutic methods thereof
US7446131B1 (en) 2004-06-10 2008-11-04 The United States Of America As Represented By The Secretary Of Agriculture Porous polymeric matrices made of natural polymers and synthetic polymers and optionally at least one cation and methods of making
JP2008513159A (en) * 2004-09-21 2008-05-01 マサチューセッツ・インスティチュート・オブ・テクノロジー Gradient frame and its creation method
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
EP1901789A2 (en) * 2005-06-30 2008-03-26 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
US7815926B2 (en) * 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
CA2518298A1 (en) * 2005-09-06 2007-03-06 Chaimed Technologies Inc. Biodegradable polymers, their preparation and their use for the manufacture of bandages
WO2007070141A1 (en) 2005-09-12 2007-06-21 Proxy Biomedical Limited Soft tissue implants and methods for making same
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
ES2452595T3 (en) 2005-10-13 2014-04-02 Anthrogenesis Corporation Immunomodulation using placental stem cells
BRPI0504797B1 (en) * 2005-10-27 2020-02-04 Pele Nova Biotecnologia S A topical formulation, cosmetic treatment method for skin rejuvenation, cosmetic treatment method and use of a formulation
EP2021536B1 (en) * 2006-04-24 2014-02-26 Coloplast A/S Non-woven structures produced by a non-toxic dry solvent spinning process
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US20080131522A1 (en) * 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
CN101622007A (en) 2006-10-06 2010-01-06 人类起源公司 Natural (end peptide) placental collagen compositions
FR2908290B3 (en) * 2006-11-10 2009-01-09 Symatese Soc Par Actions Simpl DEVICE FOR REGENERATING HUMAN DERMA AND METHOD OF MANUFACTURING THE SAME
FR2908289B1 (en) * 2006-11-10 2009-01-23 Symatese Soc Par Actions Simpl DEVICE FOR REGENERATING THE DERME AND METHOD FOR MANUFACTURING THE SAME.
US9056151B2 (en) * 2007-02-12 2015-06-16 Warsaw Orthopedic, Inc. Methods for collagen processing and products using processed collagen
DK2120977T3 (en) 2007-02-12 2013-08-12 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
WO2008125858A2 (en) * 2007-04-16 2008-10-23 Tissue Science Laboratories Plc Bone implant
US20100179639A1 (en) * 2007-04-16 2010-07-15 Stephen Bloor Vascular implant
US20080293637A1 (en) 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
WO2009043052A1 (en) * 2007-09-27 2009-04-02 Columbia University Methods and systems for forming biocompatible materials
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
WO2009065116A1 (en) 2007-11-16 2009-05-22 Aspect Pharmaceuticals Llc Compositions and methods for treating purpura
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9308068B2 (en) 2007-12-03 2016-04-12 Sofradim Production Implant for parastomal hernia
HUE025522T2 (en) 2007-12-03 2016-02-29 Tenaxis Medical Inc Biocompatible phase invertible proteinaceous compositions
AU2008345047A1 (en) 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein particles, particle devices and methods thereof
WO2009086535A2 (en) * 2007-12-27 2009-07-09 The Trustees Of Columbia University In The City Of New York Systems and methods for forming patterned extracellular matrix materials
KR101608548B1 (en) 2008-03-05 2016-04-01 케이씨아이 라이센싱 인코포레이티드 Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site
CA2717725A1 (en) * 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
PL2288376T3 (en) 2008-04-18 2016-07-29 Collplant Ltd Methods of generating and using procollagen
US9242026B2 (en) 2008-06-27 2016-01-26 Sofradim Production Biosynthetic implant for soft tissue repair
US8237009B2 (en) * 2008-06-30 2012-08-07 Polyremedy, Inc. Custom patterned wound dressings having patterned fluid flow barriers and methods of manufacturing and using same
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
WO2010019788A1 (en) 2008-08-13 2010-02-18 Smed-Ta/Td. Llc Drug delivery implants
US9616205B2 (en) 2008-08-13 2017-04-11 Smed-Ta/Td, Llc Drug delivery implants
US9700431B2 (en) 2008-08-13 2017-07-11 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
CA2734183C (en) * 2008-08-13 2016-11-01 Smed-Ta/Td, Llc Orthopaedic implant with spatially varying porosity
US10842645B2 (en) 2008-08-13 2020-11-24 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
US20100042213A1 (en) * 2008-08-13 2010-02-18 Nebosky Paul S Drug delivery implants
WO2010025386A1 (en) * 2008-08-29 2010-03-04 Smed-Ta/Td, Llc Orthopaedic implant
EP2324064B1 (en) 2008-09-02 2017-11-08 Tautona Group LP Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US20100274362A1 (en) * 2009-01-15 2010-10-28 Avner Yayon Cartilage particle tissue mixtures optionally combined with a cancellous construct
US8556990B2 (en) * 2009-02-23 2013-10-15 Barry K. Bartee Reinforced PTFE medical barriers
DK2413894T3 (en) * 2009-04-02 2017-04-03 Allergan Inc HIGHLY FORMED HYDROGLES FOR SOFTWARE STRENGTH
WO2010132673A1 (en) 2009-05-13 2010-11-18 Keraplast Technologies, Ltd. Biopolymer materials
EP2456399B1 (en) * 2009-06-25 2013-10-23 Optonol Ltd. Fiber matrix for maintaining space in soft tissues
FR2949688B1 (en) 2009-09-04 2012-08-24 Sofradim Production FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER
CA2780549C (en) 2009-11-12 2017-01-03 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
WO2011098367A2 (en) 2010-02-12 2011-08-18 Universität Zürich Method for in-vitro production of tissue engineered auto- and allografts suitable for guarded cryopreservation
SG186837A1 (en) 2010-03-01 2013-02-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve and methods associated therewith
AU2010348090B2 (en) 2010-03-12 2015-09-03 Allergan Industrie Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition
US8814842B2 (en) 2010-03-16 2014-08-26 Kci Licensing, Inc. Delivery-and-fluid-storage bridges for use with reduced-pressure systems
ES2729994T3 (en) 2010-03-22 2019-11-07 Allergan Inc Crosslinked polysaccharide and protein polysaccharide hydrogels for soft tissue augmentation
US8460691B2 (en) 2010-04-23 2013-06-11 Warsaw Orthopedic, Inc. Fenestrated wound repair scaffold
US8790699B2 (en) 2010-04-23 2014-07-29 Warsaw Orthpedic, Inc. Foam-formed collagen strand
AU2011276503B2 (en) 2010-06-28 2015-09-17 Colibri Heart Value LLC Method and apparatus for the endoluminal delivery of intravascular devices
US10065046B2 (en) * 2010-07-15 2018-09-04 Fibralign Corporation Conductive biopolymer implant for enhancing tissue repair and regeneration using electromagnetic fields
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US9724308B2 (en) 2010-09-10 2017-08-08 Fibralign Corporation Biodegradable multilayer constructs
SG10201601962WA (en) 2010-12-14 2016-04-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN102028973B (en) * 2010-12-31 2014-02-26 南昌大学 Preparation method and application of silicon rubber/collagen-based porous skin scaffold material
GB2488749A (en) * 2011-01-31 2012-09-12 Systagenix Wound Man Ip Co Bv Laminated silicone coated wound dressing
FR2972626B1 (en) 2011-03-16 2014-04-11 Sofradim Production PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED
PL2714059T3 (en) 2011-06-01 2019-04-30 Celularity Inc Treatment of pain using placental stem cells
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
CN103702659B (en) 2011-06-03 2016-12-21 阿勒根公司 Dermal filler composition including antioxidant
FR2977789B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
FR2977790B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
WO2013046058A2 (en) 2011-09-30 2013-04-04 Sofradim Production Reversible stiffening of light weight mesh
US9861532B2 (en) 2011-12-16 2018-01-09 Kci Licensing, Inc. Releasable medical drapes
US10940047B2 (en) 2011-12-16 2021-03-09 Kci Licensing, Inc. Sealing systems and methods employing a hybrid switchable drape
FR2985170B1 (en) 2011-12-29 2014-01-24 Sofradim Production PROSTHESIS FOR INGUINAL HERNIA
FR2985271B1 (en) 2011-12-29 2014-01-24 Sofradim Production KNITTED PICOTS
US11944519B2 (en) 2012-01-18 2024-04-02 Worldwide Innovative Healthcare, Inc. Unbacked and modifiable tapes and skin dressings
WO2013110008A1 (en) * 2012-01-18 2013-07-25 Worldwide Innovative Healthcare, Inc. Modifiable occlusive skin dressing
FR2994185B1 (en) 2012-08-02 2015-07-31 Sofradim Production PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER
FR2995788B1 (en) 2012-09-25 2014-09-26 Sofradim Production HEMOSTATIC PATCH AND PREPARATION METHOD
FR2995778B1 (en) 2012-09-25 2015-06-26 Sofradim Production ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME
FR2995779B1 (en) 2012-09-25 2015-09-25 Sofradim Production PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION
AU2013322268B2 (en) 2012-09-28 2017-08-31 Sofradim Production Packaging for a hernia repair device
SG11201503860RA (en) 2012-11-16 2015-06-29 Kci Licensing Inc Medical drape with pattern adhesive layers and method of manufacturing same
JP6049901B2 (en) 2012-11-27 2016-12-21 ユタ−イナ ディーディーエス アンド アドバンスト セラピューティクス リサーチ センター Biodegradable microbeads with improved ability to adsorb anticancer agents containing anionic polymer and method for producing the same
US9526491B2 (en) 2013-03-08 2016-12-27 William T. MCCLELLAN Dermal tabs
JP6600299B2 (en) 2013-05-10 2019-10-30 ザ チルドレンズ メディカル センター コーポレーション Wound healing and tissue engineering
FR3006581B1 (en) 2013-06-07 2016-07-22 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
FR3006578B1 (en) 2013-06-07 2015-05-29 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
US9993577B2 (en) 2013-07-01 2018-06-12 Trustees Of Boston University Dissolvable hydrogel compositions for wound management and methods of use
EP3062753B1 (en) 2013-10-28 2018-11-21 KCI Licensing, Inc. Hybrid sealing tape
EP3744361A1 (en) 2013-10-30 2020-12-02 KCI Licensing, Inc. Absorbent conduit and system
CN110652396B (en) 2013-10-30 2021-11-23 3M创新知识产权公司 Dressing with perforations of different sizes
US9956120B2 (en) 2013-10-30 2018-05-01 Kci Licensing, Inc. Dressing with sealing and retention interface
EP3513773A1 (en) 2013-10-30 2019-07-24 KCI Licensing, Inc. Condensate absorbing and dissipating system
GB2536174B (en) * 2013-12-17 2020-12-16 Dtherapeutics Llc Devices, systems and methods for tissue engineering of luminal grafts
US11000285B2 (en) * 2013-12-17 2021-05-11 3Dt Holdings, Llc Luminal grafts and methods of making and using the same
CA2940730C (en) 2014-02-28 2022-07-26 Kci Licensing, Inc. Hybrid drape having a gel-coated perforated mesh
US11026844B2 (en) 2014-03-03 2021-06-08 Kci Licensing, Inc. Low profile flexible pressure transmission conduit
US10406266B2 (en) 2014-05-02 2019-09-10 Kci Licensing, Inc. Fluid storage devices, systems, and methods
CN103948960B (en) * 2014-05-20 2016-01-13 四川大学 A kind of containing nanometer silver porous silicone rubber/polyurethane double-layered artificial skin and preparation method thereof
EP3281616B1 (en) 2014-06-05 2020-01-01 KCI Licensing, Inc. Dressing with fluid acquisition and distribution characteristics
JP7099822B2 (en) * 2014-08-28 2022-07-12 ミメディクス グループ インコーポレイテッド Collagen-enhanced tissue graft
EP3000489B1 (en) 2014-09-24 2017-04-05 Sofradim Production Method for preparing an anti-adhesion barrier film
EP3000432B1 (en) 2014-09-29 2022-05-04 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
EP3000433B1 (en) 2014-09-29 2022-09-21 Sofradim Production Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
EP3029189B1 (en) 2014-12-05 2021-08-11 Sofradim Production Prosthetic porous knit, method of making same and hernia prosthesis
US10398604B2 (en) 2014-12-17 2019-09-03 Kci Licensing, Inc. Dressing with offloading capability
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
EP3059255B1 (en) 2015-02-17 2020-05-13 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
EP3085337B1 (en) 2015-04-24 2022-09-14 Sofradim Production Prosthesis for supporting a breast structure
US11246975B2 (en) 2015-05-08 2022-02-15 Kci Licensing, Inc. Low acuity dressing with integral pump
ES2676072T3 (en) 2015-06-19 2018-07-16 Sofradim Production Synthetic prosthesis comprising a knitted fabric and a non-porous film and method of forming it
EP3344205B1 (en) 2015-09-01 2020-09-30 KCI Licensing, Inc. Dressing with increased apposition force
EP3349807B1 (en) 2015-09-17 2021-02-24 3M Innovative Properties Company Hybrid silicone and acrylic adhesive cover for use with wound treatment
EP3195830B1 (en) 2016-01-25 2020-11-18 Sofradim Production Prosthesis for hernia repair
US10470872B1 (en) 2016-04-07 2019-11-12 Michael A. Scarpone Implantable articles for attaching tendons and/or ligaments to bone and/or cartilage, assemblies thereof, and methods of use thereof
EP3312325B1 (en) 2016-10-21 2021-09-22 Sofradim Production Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
EP3398554A1 (en) 2017-05-02 2018-11-07 Sofradim Production Prosthesis for inguinal hernia repair
WO2019051476A1 (en) 2017-09-11 2019-03-14 Incubar, LLC Conduit vascular implant sealing device for reducing endoleak
CN107998908B (en) * 2017-12-14 2021-04-13 北京林业大学 Preparation method of super-hydrophilic organic membrane based on micro-nano substrate
CN109248337B (en) * 2018-09-19 2021-03-30 深圳齐康医疗器械有限公司 Artificial dermis repairing material and preparation method thereof
EP3653171A1 (en) 2018-11-16 2020-05-20 Sofradim Production Implants suitable for soft tissue repair
CN111700713A (en) * 2020-06-24 2020-09-25 福建华民生物科技有限公司 Artificial skin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1236720B (en) * 1962-05-17 1967-03-16 Dr Med Gerhard Ott Dermal prosthesis
US3875937A (en) * 1963-10-31 1975-04-08 American Cyanamid Co Surgical dressings of absorbable polymers
US3526224A (en) * 1967-06-08 1970-09-01 Johnson & Johnson Dressing
GB1246179A (en) * 1968-03-06 1971-09-15 Ceskoslovenska Akademie Ved Hydrogel laminates and method of manufacture
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3699963A (en) * 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
US3846353A (en) * 1970-06-08 1974-11-05 Department Of Health Education Nonthrombogenic plastic material and method for making the same
US3742955A (en) * 1970-09-29 1973-07-03 Fmc Corp Fibrous collagen derived product having hemostatic and wound binding properties
GB1399824A (en) * 1971-08-16 1975-07-02 Mar Pha Etu Expl Marques Heparin esters
US3844989A (en) * 1971-12-23 1974-10-29 Toray Industries Shampooer with rotary foam generating means anti-thrombogenic polymer compositions with internally bound heparin
JPS5416979B2 (en) * 1972-01-08 1979-06-26
US3849238A (en) * 1972-04-07 1974-11-19 S Ronel Artificial skin
US3800792A (en) * 1972-04-17 1974-04-02 Johnson & Johnson Laminated collagen film dressing
US3810473A (en) * 1972-12-04 1974-05-14 Avicon Inc Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties
US3896802A (en) * 1974-04-19 1975-07-29 American Cyanamid Co Flexible flocked dressing
US3903882A (en) * 1974-04-19 1975-09-09 American Cyanamid Co Composite dressing

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282300A1 (en) * 2003-08-26 2012-11-08 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US9107937B2 (en) * 2003-08-26 2015-08-18 Gel-Del Technologies, Inc. Wound treatments with crosslinked protein amorphous biomaterials
US9999705B2 (en) 2003-08-26 2018-06-19 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof

Also Published As

Publication number Publication date
US4060081A (en) 1977-11-29
JPS5727834B2 (en) 1982-06-12
GB1518748A (en) 1978-07-26
JPS5238796A (en) 1977-03-25
DE2631909A1 (en) 1977-02-10
DE2631909C2 (en) 1986-09-04
FR2332863A1 (en) 1977-06-24
FR2332863B1 (en) 1981-09-25

Similar Documents

Publication Publication Date Title
CA1071814A (en) Multilayer membrane useful as synthetic skin
US5171273A (en) Synthetic collagen orthopaedic structures such as grafts, tendons and other structures
US5166187A (en) Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their application in human medicine
US4280954A (en) Crosslinked collagen-mucopolysaccharide composite materials
Yannas et al. Design of an artificial skin. I. Basic design principles
Yannas Tissue regeneration by use of collagen-glycosaminoglycan copolymers
CA1087610A (en) Crosslinked collagen mucopolysaccharide composite materials
Kato et al. Mechanical properties of collagen fibres: a comparison of reconstituted and rat tail tendon fibres
Li Biologic biomaterials: tissue-derived biomaterials (collagen)
EP0637452B1 (en) Collagen membrane material for medical use and process for preparing the same
EP0177573B1 (en) Biodegradable matrix and methods for producing same
Berthod et al. Optimization of thickness, pore size and mechanical properties of a biomaterial designed for deep burn coverage
EP0943346B1 (en) Collagen laminate material and process for producing the same
EP1676592B1 (en) Membrane comprising collagen for use in guided tissue regeneration
US5264214A (en) Composition for bone repair
EP0444157B1 (en) Collagen-polymer conjugates
US5376375A (en) Method of augmenting tissue using collagen-polymer conjugates
EP0781564A2 (en) Material for medical use comprising human-derived natural collagen membrane
EP0160025A1 (en) Biomaterial.
Hafemann et al. Cross-linking by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) of a collagen/elastin membrane meant to be used as a dermal substitute: effects on physical, biochemical and biological features in vitro
WO2000016817A1 (en) Dermal scaffold using neutralized chitosan sponge or neutralized chitosan/collagen mixed sponge
Omura et al. A newly developed collagen/silicone bilayer membrane as a mucosal substitute: a preliminary report
Wasserman et al. Achilles tendon replacement by a collagen fiber prosthesis: morphological evaluation of neotendon formation.
IE54668B1 (en) Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressings comprising same
Gorham et al. The in vitro assessment of a collagen/vicryl (polyglactin) composite film together with candidate suture materials for use in urinary tract surgery: I. Physical testing

Legal Events

Date Code Title Description
MKEX Expiry